


09/29/2006

(Registry / Caplus)

for formula (I)

wherein χ^2 = o-phenylene or
1/2-cyclohexenylene

L1	STR
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100



G1 C, O, S, N

Structure attributes must be viewed using STN Express query preparation.

FULL SEARCH INITIATED 10:34:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3104 TO ITERATE

```
100.0% PROCESSED      3104 ITERATIONS
SEARCH TIME: 00.00.01
```

559 ANSWERS

L2 559 SEA SSS FUL L1

COST IN U.S. DOLLARS

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 10:34:58 ON 29 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 29 Sep 2006 VOL 145 ISS 15
FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3

19 L2

=> d ibib abs hitstr 1-19

L3 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:636088 CAPLUS
 DOCUMENT NUMBER: 145:76629
 TITLE: DNA damage repair inhibitors for the treatment of cancer
 INVENTOR(S): Ashworth, Alan; Jackson, Stephen; Martin, Niail; Smith, Graeme; O'Connor, Mark
 PATENT ASSIGNEE(S): UK
 SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 1,474.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142231	A1	20060629	US 2005-245735	20051006
US 2005227919	A1	20051013	US 2004-1474	20041130
PRIORITY APPL. INFO.:			GB 2003-27844	A 20031201
			US 2003-526244P	P 20031201
			US 2004-1474	A2 20041130


AB The invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in homologous recombination (HR)-dependent DNA double strand break (DSB) repair. The invention provides methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, e.g. PARP.

IT 763111-49-5, KU0058948
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (DNA damage repair inhibitors for treatment of cancer)

RN 763111-49-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L3 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:625370 CAPLUS
 DOCUMENT NUMBER: 145:240942
 TITLE: Anti-HIV activity of stilbene-related heterocyclic compounds
 AUTHOR(S): Bedoya, Luis M.; Del Olmo, Esther; Sancho, Rocio; Barborza, Bianca; Beltran, Manuela; Garcia-Cadenas, Ana
 CORPORATE SOURCE: E.; Sanchez-Palomino, Sonsoles; Lopez-Perez, Jose L.; Munoz, Eduardo; San Feliciano, Arturo; Alcamí, Jose
 Unidad de Immunopatología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, 28220, Spain
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(15), 4075-4079
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Viral transcription has not been routinely targeted in the development of new antiviral drugs. This crucial step of the viral cycle depends on the concerted action of cellular and viral proteins such as NF- κ B and Tat. In the present study, stilbene-related heterocyclic compds. including benzaldehyde, phthalazinone, imidazoindole and pyrimidoindole derivs. are tested for their anti-HIV activity. Original assays based on recombinant viruses were used to evaluate HIV replication inhibition and stably transfected cell lines were used to evaluate inhibition of Tat and NF- κ B proteins. Some of the stilbene-related heterocyclic compds. analyzed displayed anti-HIV activity through interference with NF- κ B and Tat function. Moreover, compds. inhibiting both targets displayed a stronger activity on viral replication.


IT 10001-31-7P 365222-04-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-HIV activity of stilbene-related heterocyclic compds.)

RN 10001-31-7 CAPLUS

CN 1(2H)-Phthalazinone, 4-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 365222-04-4 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L3 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:315164 CAPLUS
 DOCUMENT NUMBER: 145:300
 TITLE: Vasorelaxant activity of phthalazinones and related compounds
 AUTHOR(S): Del Olmo, Esther; Barboza, Bianca; Ybarra, M. Ines; Lopez-Perez, Jose Luis; Carron, Rosalia; Sevilla, M. Angeles; Boselli, Cinthia; San Feliciano, Arturo
 CORPORATE SOURCE: Departamento de Quimica Farmaceutica, Ciset, Facultad de Farmacia, Universidad de Salamanca, Salamanca, 37007, Spain
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2786-2790
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I


AB Several series of dihydrostilbenamide, imidazo[2,1-a]isoindole, pyrimido[2,1-a]isoindole and phthalazinone derivs. were obtained and their vasorelaxant activity was measured on isolated rat aorta rings pre-contracted with phenylephrine (10-5 M). Some phthalazinones attained, practically, the total relaxation of the organ at micromolar concns. For the most potent compound I (EC50 = 0.43 µM) the affinities for α1A, α1B and α1D adrenergic sub-receptors were determined
 IT 10001-31-7P 365222-04-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Vasorelaxant activity of phthalazinones and related compds.)
 RN 10001-31-7 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:16499 CAPLUS
 DOCUMENT NUMBER: 144:142019
 TITLE: Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase
 AUTHOR(S): Cockcroft, Xiao-ling; Dillon, Krystyna J.; Dixon, Lesley; Drzewiecki, Jan; Kerrigan, Frank; Loh, Vincent
 CORPORATE SOURCE: M.; Martin, Niall M. B.; Menear, Keith A.; Smith, Graeme C. M.
 SOURCE: KUDOS Pharmaceuticals Ltd, Cambridge, CB4 0WG, UK
 Bioorg. Med. Chem. Lett. (2006), 16(4), 1040-1044
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We have previously described the discovery of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors based on a phthalazinone scaffold. Subsequent optimization of inhibitory activity, metabolic stability and pharmacokinetic parameters has led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-one PARP-1 inhibitors which retain low nM cellular activity and show good stability in vivo and efficacy in cell based models.
 IT 763111-49-5P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (phthalazinones and optimization and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase)
 RN 763111-49-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)




IT 763113-99-1P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (phthalazinones and optimization and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase)
 RN 763113-99-1 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[(3,4-dihydro-4-oxo-1-

L3 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365222-04-4 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 phthalazinyl)methyl]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 420847-65-0P 763111-46-2P 763111-48-4P
 763111-83-7P 763111-87-1P 763111-89-3P
 763111-91-7P 763111-94-0P 763111-99-5P
 763112-04-5P 763112-32-9P 763113-35-5P
 763113-36-6P 763113-86-6P 763114-00-7P
 763114-01-8P 848136-22-1P 848136-25-4P
 848136-26-5P 848136-45-8P 848136-47-0P
 848136-48-1P 848136-83-4P 848136-84-5P
 848136-90-3P 853650-62-1P 874116-43-5P
 874116-44-6P 874116-45-7P 874116-46-8P
 874116-47-9P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (phthalazinones and optimization and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase)
 RN 420847-65-0 CAPLUS
 CN Propanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763111-46-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 (9CI) (CA INDEX NAME)




RN 763111-48-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro- (9CI) (CA INDEX NAME)




RN 763111-83-7 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-87-1 CAPLUS
 CN Piperidine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-methyl-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763111-89-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-91-7 CAPLUS
 CN Isoquinoline,
 2-[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-piperidinyl]carbonyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 763111-94-0 CAPLUS
 CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-99-5 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 763112-04-5 CAPLUS
 CN 4-Piperidinecarboxamide, N-cyclopentyl-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-32-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763113-35-5 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(2-chloro-6-methoxy-4-pyridinyl)carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-36-6 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[3-(3-methoxyphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763113-86-6 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763114-00-7 CAPLUS
 CN Isoquinoline, 2-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 763114-01-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 848136-22-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-ethylhexahydro- (9CI) (CA INDEX NAME)




RN 848136-25-4 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 848136-26-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-(cyclopropylmethyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-45-8 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-ethylhexahydro- (9CI) (CA INDEX NAME)




RN 848136-47-0 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-48-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-(cyclopropylmethyl)-4-[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-83-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(3-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-84-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-4-[3-[(3,4-dihydro-4-
 oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-90-3 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]hexahydro-N-(4-methoxyphenyl)- (9CI) (CA
 INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853650-62-1 CAPLUS
 CN Benzamide, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-N-ethyl- (9CI)
 (CA INDEX NAME)




RN 874116-43-5 CAPLUS
 CN Benzamide, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-N-[2-
 (dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 874116-44-6 CAPLUS
 CN Morpholine, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 874116-45-7 CAPLUS
 CN 4-Piperidinecarboxamide, N-(cyclohexylmethyl)-1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 874116-46-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-cyclohexyl-4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 874116-47-9 CAPLUS
 CN 1H-1,4-Diazepine, 1-cyclohexyl-4-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 420846-72-6P 763114-26-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (phthalazinones and optimization and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase)
 RN 420846-72-6 CAPLUS
 CN Benzoic acid, 3-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 763114-26-7 CAPLUS
 CN Benzoic acid, 3-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 763111-56-4P 874116-49-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (phthalazinones and optimization and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase)
 RN 763111-56-4 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 874116-49-1 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L3 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:523263 CAPLUS
 DOCUMENT NUMBER: 143:53462
 TITLE: DNA damage repair inhibitors for treatment of cancer
 INVENTOR(S): Ashworth, Alan; Jackson, Stephen; Martin, Niall; Smith, Graeme
 PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; The Institute of Cancer Research
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053662	A1	20050616	WO 2004-GB5025	20041130
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004294790	A1	20050616	AU 2004-294790	20041130
CA 2547077	AA	20050616	CA 2004-2547077	20041130
EP 1684736	A1	20060802	EP 2004-798705	20041130
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
PRIORITY APPLN. INFO.:			GB 2003-27844	A 20031201
			US 2003-526244P	P 20031201
			WO 2004-GB5025	W 20041130

AB The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
 IT 763111-49-5, KU 0058948
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (DNA damage repair inhibitors for treatment of cancer)
 RN 763111-49-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2005:331915 CAPLUS
 DOCUMENT NUMBER: 143:43842
 TITLE: Phthalazinones. Part 1: the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
 AUTHOR(S): Loh, Vincent M.; Cockcroft, Xiao-Ling; Dillon, Krystyna J.; Dixon, Lesley; Drzewiecki, Jan; Eversley, Penny J.; Gomez, Sylvie; Hoare, Janet; Kerrigan, Frank; Matthews, Ian T. W.; Menear, Keith A.; Martin, Niall M. B.; Newton, Roger F.; Paul, Jane; Smith, Graeme C. M.; Vile, Julia; Whittle, Alan J.
 CORPORATE SOURCE: KUDOS Horsham Ltd, Horsham, West Sussex, RH13 5PX, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(9), 2235-2238
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:43842

AB Screening of the Maybridge compound collection identified 4-arylphthalazinones as micromolar inhibitors of PARP-1 catalytic activity. Subsequent optimization of both inhibitory activity and metabolic stability led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-ones with low nanomolar, cellular activity as PARP-1 inhibitors and promising metabolic stability in vitro.
 IT 420846-57-7P 623578-09-6P 623578-40-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phthalazinone derivs. using aminophenylmethyl phthalazinone as synthetic intermediate)
 RN 420846-57-7 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3-aminophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 623578-09-6 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3-amino-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-40-5 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-amino-4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 623578-55-2 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-amino-4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 420846-84-0 420846-86-2 420847-64-9
420847-65-0 420847-66-1 420847-70-7
853650-53-0 853650-54-1 853650-55-2
853650-56-3 853650-57-4 853650-58-5
853650-59-6 853650-60-9 853650-62-1
RL: PAC (Pharmacological activity); BIOL (Biological study)
(study of phthalazinone derivs. as inhibitors of poly(ADP-ribose)polymerase and study of their structure-activity relationship)
RN 420846-84-0 CAPLUS
CN Acetamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420846-86-2 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-(acetyloxy)phenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-64-9 CAPLUS
CN Butanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420847-65-0 CAPLUS
CN Propanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-66-1 CAPLUS
CN Propanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 420847-70-7 CAPLUS
CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853650-53-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 853650-54-1 CAPLUS
 CN 1H-Pyrazole-4-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-1-(4-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853650-55-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-6-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 853650-56-3 CAPLUS
 CN 5-Thiazolecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-4-methyl-2-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853650-57-4 CAPLUS
 CN [2,3'-Bithiophene]-5-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 853650-58-5 CAPLUS
 CN Acetamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853650-59-6 CAPLUS
 CN Carbamic acid, [3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 853650-60-9 CAPLUS
 CN Ethanesulfonamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 853650-62-1 CAPLUS
CN Benzamide, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-N-ethyl- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:317509 CAPLUS
DOCUMENT NUMBER: 143:54272
TITLE: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
AUTHOR(S): Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M.

B.: Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan
CORPORATE SOURCE: Cancer Research UK Gene Function and Regulation Group,
London, SW3 6JB, UK

SOURCE: Nature (London, United Kingdom) (2005), 434(7035), 917-921

CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an enzyme

involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle

arrest and subsequent apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways

cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.

IT 763111-49-5


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(targeting DNA repair defect in BRCA mutant cells as therapeutic strategy)

RN 763111-49-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:238692 CAPLUS

DOCUMENT NUMBER: 142:316849

TITLE: Preparation of phthalazinones as PARP inhibitors

INVENTOR(S): Martin, Niall Morrison Barr; Smith, Graeme Cameron; Jackson, Stephen Philip; Loh, Vincent M., Jr.; Cockcroft, Xiao-Ling Fan; Matthews, Ian Timothy Williams; Meneer, Keith Allan; Kerrigan, Frank; Ashworth, Alan

PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; Maybridge Limited
U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S. Ser. No. 799,154.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005059663	A1	20050317	US 2004-876080	20040624
US 2006149059	A1	20060706	US 2005-318155	20051223
PRIORITY APPLN. INFO.:			GB 2003-5681	A 20030312
			US 2003-454995P	P 20030314
			US 2003-493399P	P 20030806
			US 2003-526244P	P 20031201
			US 2004-799154	A2 20040312
			US 2004-876080	A3 20040624

OTHER SOURCE(S): MARPAT 142:316849
GI



AB The title compds. [I: A and B together represent (un)substituted fused aromatic ring; X = NRx or CRxRy; if X = NRx then n = 1 or 2 and if X = CRxRy then n = 1; Rx = H, (un)substituted C1-20 alkyl, C5-20 aryl, C3-20

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry = H, OH, NH2; or Rx and Ry may together form a spiro(C3-7)cycloalkyl or heterocyclyl group; R11 and R12 are both H, or when X = CRxRy, R11, R12, Rx and Ry, together with the carbon atoms to which they are attached, may form (un)substituted fused arom. ring; R1 = H, halo), were prepd. Thus, reacting 3-(4-oxo-3,4-dihydrophthalazin-1-ylmethyl)benzoic acid (prepn. given) with tert-Bu 1-piperazinecarboxylate afforded 77% II which had

IC50 of < 0.02 µM against PARP. All compds. I tested had a IC50 of < 0.1 µM in the PARP assay. The pharmaceutical compn. comprising the compd. I is claimed.

IT 763111-46-2P 763111-47-3P 763111-48-4P


763111-49-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phthalazinones as PARP inhibitors for use in the treatment

of cancer which is deficient in HR dependent DNA DSB repair pathway)

RN 763111-46-2 CAPLUS


CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 763111-47-3 CAPLUS


CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763111-48-4 CAPLUS


CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)



RN 763111-49-5 CAPLUS

CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 763111-50-8P 763111-51-9P 763111-52-0P
763111-53-1P 763111-54-2P 763111-55-3P
763111-56-4P 763111-57-5P 763111-58-6P
763111-59-7P 763111-60-0P 763111-61-1P
763111-67-7P 763111-68-8P 763111-69-9P
763111-70-2P 763111-71-3P 763111-72-4P
763111-73-5P 763111-74-6P 763111-75-7P
763111-76-8P 763111-77-9P 763111-78-0P
763111-79-1P 763111-80-4P 763111-81-5P
763111-82-6P 763111-83-7P 763111-85-9P
763111-89-3P 763111-91-7P 763111-92-8P
763111-93-9P 763111-94-0P 763111-95-1P
763111-96-2P 763111-97-3P 763111-98-4P
763111-99-5P 763112-00-1P 763112-01-2P
763112-02-3P 763112-03-4P 763112-04-5P
763112-05-6P 763112-06-7P 763112-07-8P
763112-08-9P 763112-09-0P 763112-10-3P
763112-11-4P 763112-12-5P 763112-13-6P
763112-14-7P 763112-15-8P 763112-16-9P
763112-17-0P 763112-18-1P 763112-19-2P
763112-20-5P 763112-21-6P 763112-22-7P
763112-23-8P 763112-24-9P 763112-25-0P
763112-26-1P 763112-27-2P 763112-29-4P
763112-31-8P 763112-32-9P 763112-34-1P
763112-35-2P 763112-37-4P 763112-39-6P
763112-40-9P 763112-42-1P 763112-43-2P
763112-44-3P 763112-45-4P 763112-46-5P
763112-47-6P 763112-48-7P 763112-49-8P
763112-50-1P 763112-51-2P 763112-52-3P
763112-53-4P 763112-54-5P 763112-55-6P
763112-56-7P 763112-57-8P 763112-58-9P
763112-59-0P 763112-60-3P 763112-61-4P
763112-62-5P 763112-63-6P 763112-64-7P
763112-65-8P 763112-66-9P 763112-67-0P
763112-68-1P 763112-69-2P 763112-70-5P
763112-71-6P 763112-72-7P 763112-73-8P
763112-74-9P 763112-75-0P 763112-76-1P
763112-77-2P 763112-78-3P 763112-79-4P
763112-80-7P 763112-81-8P 763112-82-9P
763112-83-0P 763112-84-1P 763112-85-2P
763112-86-3P 763112-87-4P 763112-88-5P


L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

763112-89-6P 763112-90-9P 763112-91-0P
763112-92-1P 763112-93-2P 763112-94-3P
763112-95-4P 763112-96-5P 763112-97-6P
763112-98-7P 763112-99-8P 763113-00-4P
763113-01-5P 763113-20-8P 763113-21-9P
763113-22-0P 763113-23-1P 763113-24-2P
763113-25-3P 763113-26-4P 763113-27-5P
763113-29-7P 763113-30-0P 763113-31-1P
763113-32-2P 763113-33-3P 763113-34-4P
763113-37-7P 763113-38-8P 763113-73-1P
763113-74-2P 763113-75-3P 763113-76-4P
763113-77-5P 763113-78-6P 763113-79-7P
763113-80-0P 763113-81-1P 763113-82-2P
763113-83-3P 763113-84-4P 763113-85-5P
763113-86-6P 763113-87-7P 763113-88-8P
763113-89-9P 763113-90-2P 763113-91-3P
763113-92-4P 763113-93-5P 763113-94-6P
763113-95-7P 763113-96-8P 763113-97-9P
763113-98-0P 763113-99-1P 763114-00-7P
763114-01-8P 763114-02-9P 763114-03-0P
763114-04-1P 763114-05-2P 763114-06-3P
763114-07-4P 763114-08-5P 763114-09-6P
763114-10-9P 763114-11-0P 763114-12-1P
763114-13-2P 763114-14-3P 763114-15-4P
763114-16-5P 763114-17-6P 763114-18-7P
763114-19-8P 763114-20-1P 763114-21-2P
848135-58-0P 848135-59-1P 848135-60-4P
848135-65-9P 848135-67-1P 848135-68-2P
848135-70-6P 848135-71-7P 848135-73-9P
848135-74-0P 848135-76-2P 848135-78-4P
848135-80-8P 848135-82-0P 848135-84-2P
848135-86-4P 848135-88-6P 848135-90-0P
848135-94-4P 848135-98-8P 848136-03-8P
848136-05-0P 848136-07-2P 848136-09-4P
848136-11-8P 848136-13-0P 848136-15-2P
848136-17-4P 848136-20-9P 848136-21-0P
848136-22-1P 848136-23-2P 848136-24-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phthalazinones as PARP inhibitors for use in the treatment of cancer which is deficient in HR dependent DNA DSB repair pathway)


RN 763111-50-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-51-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 763111-52-0 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(4-bromo-2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-53-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 763111-54-2 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(5-propyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-55-3 CAPLUS
 CN 1H-1,4-Diazepine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-[(4-bromo-2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 763111-56-4 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-57-5 CAPLUS
 CN 1H-1,4-Diazepine-1-ethanol, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763111-58-6 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-59-7 CAPLUS
 CN Piperazine, 1-[(5-cyano-2-pyridinyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-60-0 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-61-1 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)




RN 763111-67-7 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-68-8 CAPLUS
 CN Piperidine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 763111-69-9 CAPLUS
 CN Piperidine, 4-(4-chlorobenzoyl)-1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-70-2 CAPLUS
 CN Spiro[piperidine-4,1'-(1H)pyrido[3,4-b]indole], 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-2',3',4',9'-tetrahydro- (9CI) (CA INDEX NAME)




RN 763111-71-3 CAPLUS
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-72-4 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[2,6-dinitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 763111-73-5 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-phenyl-1,2,4-thiadiazol-5-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-74-6 CAPLUS
 CN Piperazine, 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-75-7 CAPLUS
 CN Piperazine, 1-(5-chloro-1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-76-8 CAPLUS
 CN Piperazine, 1-(cyclohexylcarbonyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-77-9 CAPLUS
 CN 3-Thiophenecarboxylic acid, 5-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-78-0 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(3-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 763111-79-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-80-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 763111-81-5 CAPLUS
 CN 1,3-Dioxolo[4,5-g]isoquinoline, 6-[[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-82-6 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX
 NAME)




RN 763111-83-7 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX
 NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-85-9 CAPLUS
 CN Piperidine,
 1-[[[1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-
 piperidinyl]carbonyl]-2-methyl]- (9CI) (CA INDEX NAME)




RN 763111-89-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]-N-(2-(2-thienyl)ethyl)- (9CI) (CA INDEX
 NAME)


L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763111-91-7 CAPLUS
 CN Isoquinoline,
 2-[[[1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-piperidinyl]carbonyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA
 INDEX NAME)




RN 763111-92-8 CAPLUS
 CN Isoquinoline,
 2-[[[1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-piperidinyl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763111-93-9 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[4-(1,1-dimethylethyl)cyclohexyl]- (9CI) (CA INDEX NAME)




RN 763111-94-0 CAPLUS
 CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 763111-95-1 CAPLUS
 CN 4-Piperidinecarboxamide, N-[(1S)-2,3-dihydro-1H-inden-1-yl]-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-96-2 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 763111-97-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-98-4 CAPLUS
 CN 4-Piperidinecarboxamide, N-(cyclohexylmethyl)-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-99-5 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-00-1 CAPLUS
 CN 4-Piperidinecarboxamide, N-(cyclopropylmethyl)-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (5CI) (CA INDEX NAME)




RN 763112-01-2 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methylcyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-02-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-N,N-di-2-propenyl)- (9CI) (CA INDEX NAME)




RN 763112-03-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-N-(1-ethynylcyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-04-5 CAPLUS
 CN 4-Piperidinecarboxamide, N-cyclopentyl-1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-05-6 CAPLUS
 CN 4-Piperidinecarboxamide, 1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-N-[(2S)-2-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued).




RN 763112-06-7 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-([1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-4-piperidiny]carbonyl]amino)-, ethyl ester (9CI) (CA INDEX NAME)




RN 763112-07-8 CAPLUS
 CN 4-Piperidinecarboxamide, 1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-N-[1-(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-08-9 CAPLUS
 CN 4-Piperidinecarboxamide, 1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 763112-09-0 CAPLUS
 CN Piperazine, 1-([bis(4-fluorophenyl)methyl]-4-([1-([3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-4-piperidiny]carbonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-10-3 CAPLUS
CN Piperazine,
1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(9CI) (CA INDEX NAME)




RN 763112-11-4 CAPLUS
CN Piperazine,
1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-4-(2-methylphenyl)-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-14-7 CAPLUS
CN Piperazine,
1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-4-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 763112-15-8 CAPLUS
CN Piperazine, 1-(4-acetylphenyl)-4-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-12-5 CAPLUS
CN Piperazine,
1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-4-(2,4-dimethylphenyl)-(9CI) (CA INDEX NAME)




RN 763112-13-6 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-16-9 CAPLUS
CN Piperazine,
1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-4-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 763112-17-0 CAPLUS
CN Piperazine,
1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-4-(2-fluorophenyl)-(9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-18-1 CAPLUS
 CN Piperazine,
 4-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]-2-methyl-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 763112-19-2 CAPLUS
 CN Piperazine,
 1-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-20-5 CAPLUS
 CN Piperazine, 1-cyclohexyl-4-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-21-6 CAPLUS
 CN Morpholine, 4-[[1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-22-7 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 763112-23-8 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(ethylsulfonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-24-9 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 763112-25-0 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[2-chlorophenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-26-1 CAPLUS
 CN Piperazine,
 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)




RN 763112-27-2 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-29-4 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 763112-31-8 CAPLUS
 CN Piperazine, 1-(butylsulfonyl)-4-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-32-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763112-34-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-(butylsulfonyl)-4-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-35-2 CAPLUS
 CN Piperazine, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-4-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)




RN 763112-37-4 CAPLUS
 CN Piperazine, 1-(2-chloro-4-fluorobenzoyl)-4-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-39-6 CAPLUS
CN Piperazine, 1-[(acetyloxy)acetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-40-9 CAPLUS
CN Piperazine, 1-[2-(acetyloxy)-2-methyl-1-oxopropyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-42-1 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-43-2 CAPLUS
CN Piperazine, 1-[(acetyloxy)phenylacetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-44-3 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-H-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 763112-45-4 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2,5-dimethyl-3-furanyl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-46-5 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-47-6 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(6-fluoro-4H-1,3-benzodioxin-8-yl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-48-7 CAPLUS
 CN Piperazine, 1-[(2,1,3-benzothiadiazol-5-ylcarbonyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-49-8 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(5-methyl-3-isoxazolyl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-50-1 CAPLUS
 CN Piperazine, 1-[2-[(benzoyloxy)methyl]benzoyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-51-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-52-3 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-53-4 CAPLUS
 CN Piperazine, 1-[(1-(4-chlorophenyl)-5-methyl-1H-imidazol-4-yl)carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-54-5 CAPLUS
 CN Piperazine, 1-[[1-[3,5-bis(trifluoromethyl)phenyl]-5-methyl-1H-1,2,3-triazol-4-yl]carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-55-6 CAPLUS
 CN Piperazine, 1-[[1-(4-chlorophenyl)-5-methyl-1H-imidazol-4-yl]carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-56-7 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-(4-methylphenyl)cyclopropyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-57-8 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1H-indol-1-yl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-58-9 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(5-isoxazolylcarbonyl)- (9CI) (CA INDEX NAME)




RN 763112-59-0 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2-benzothiazolylthio)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-60-3 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-61-4 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763112-62-5 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-63-6 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763112-64-7 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-methoxyphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763112-65-8 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 763112-66-9 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-thienylacetyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-67-0 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-68-1 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-methyl-1-oxoheptyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-69-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-ethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-70-5 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,1'-biphenyl)-4-ylacetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-71-6 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-fluorophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-72-7 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-chlorophenyl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-73-8 CAPLUS
 CN Piperazine, 1-[(3-benzodioxol-5-ylacetyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-74-9 CAPLUS
 CN Piperazine, 1-[(2,3-dihydro-1H-inden-2-yl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-75-0 CAPLUS
 CN Piperazine, 1-[(3,5-difluorophenyl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-76-1 CAPLUS
 CN Piperazine, 1-[(2,3-dihydro-1H-inden-2-yl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-77-2 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763112-78-3 CAPLUS
 CN Piperazine, 1-[(4-butoxyphenyl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-79-4 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-80-7 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(phenyl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-81-8 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-1,4-dioxobutyl]-4-
 [(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX
 NAME)




RN 763112-82-9 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(5-
 methyl-2-phenyl-4-oxazolyl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-85-2 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-
 [(4,5-dimethoxy-2-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-86-3 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3-
 (2-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-83-0 CAPLUS
 CN Piperazine, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)acetyl]-4-[(3,4-
 dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)




RN 763112-84-1 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-
 [(3S)-1-oxo-3-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-87-4 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3-
 (3-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763112-88-5 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3-
 (3-methylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-89-6 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-90-9 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-91-0 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 763112-92-1 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-93-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-dimethyl-5-[3-(trifluoromethyl)phenoxy]-1H-pyrazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-94-3 CAPLUS
 CN Piperazine,
 1-[5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-95-4 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-3-phenyl-1H-thieno[2,3-c]pyrazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-96-5 CAPLUS
 CN Piperazine,
 1-[1-[4-(4-chlorophenyl)-2-thiazolyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-97-6 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2-phenyl-4-(trifluoromethyl)-5-thiazolyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-98-7 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-methyl-2-(2-thienyl)-5-thiazolyl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-99-8 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763113-00-4 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[3-(2-methylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-01-5 CAPLUS
 CN Piperazine, 1-benzoyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-20-8 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-21-9 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[1-methyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763113-22-0 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-23-1 CAPLUS
 CN Morpholine, 4-[[4-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763113-24-2 CAPLUS
 CN Piperazine, 1-[[5-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-25-3 CAPLUS
 CN Piperazine, 1-[[5-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-(hexahydro-1H-1,4-diazepin-1-yl)-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 763113-26-4 CAPLUS
 CN Piperazine, 1-[[5-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-(4-methyl-1-piperazinyl)-1-oxopropyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-27-5 CAPLUS
 CN Piperazine, 1-[[5-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-piperidinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763113-29-7 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(4-phenylbicyclo[1.1.1]pent-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-30-0 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(1-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 763113-31-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[[3-(4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(2-methyl-1-oxo-2-pentenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-32-2 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-33-3 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[5-isoxazolylcarbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-34-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[2-methyl-1-oxoheptyl]- (9CI) (CA INDEX NAME)




RN 763113-37-7 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[(dimethylamino)acetyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-38-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-[4-morpholinylcarbonyl]- (9CI) (CA INDEX NAME)




RN 763113-73-1 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-74-2 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 763113-75-3 CAPLUS
 CN 1-Piperazinecarbothioamide, N-butyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-76-4 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 763113-77-5 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(pentafluorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-78-6 CAPLUS
 CN Benzoic acid, 4-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]thioxomethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 763113-79-7 CAPLUS
 CN Benzoic acid, 2-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]thioxomethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-80-0 CAPLUS
 CN 1-Piperazinecarbothioamide, N-(3-acetylphenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-81-1 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-82-2 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 763113-83-3 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-84-4 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 763113-85-5 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-86-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 763113-87-7 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-88-8 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 763113-89-9 CAPLUS
 CN Piperazine, 1-cyclohexyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-90-2 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 763113-91-3 CAPLUS
 CN Piperazine, 1-cyclohexyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-92-4 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 763113-93-5 CAPLUS
 CN 1-Piperazineacetamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-94-6 CAPLUS
 CN Piperazine, 1-(4-chlorophenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-95-7 CAPLUS
 CN Piperazine, 1-(4-acetylphenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-96-8 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 763113-97-9 CAPLUS
 CN 1-Piperazinecarboxaldehyde, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-98-0 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-99-1 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-00-7 CAPLUS
 CN Isoquinoline, 2-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 763114-01-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-02-9 CAPLUS
 CN 1H-1,4-Diazepine-1-ethanol, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763114-03-0 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-04-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 763114-05-2 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-06-3 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 763114-07-4 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-08-5 CAPLUS
 CN Morpholine, 4-[[4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 763114-09-6 CAPLUS
 CN 1-Piperazineethanol, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-10-9 CAPLUS
 CN 1-Piperazineethanamine, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 763114-11-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763114-12-1 CAPLUS
 CN Isoquinoline, 2-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 763114-13-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763114-14-3 CAPLUS
 CN Piperazine, 1-butyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763114-15-4 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 763114-16-5 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-1H-indol-3-yl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-17-6 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1H-indol-3-ylmethyl)]- (9CI) (CA INDEX NAME)




RN 763114-18-7 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-pyridinylmethyl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-19-8 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-thiazolylmethyl)]- (9CI) (CA INDEX NAME)




RN 763114-20-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-methylethyl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-21-2 CAPLUS
 CN 1H-1,4-Diazepine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 848135-58-0 CAPLUS
 CN Benzoic acid,
 4-[[[4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]thioxomethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-59-1 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]-4-(2,3-dimethylphenyl)]- (9CI) (CA INDEX NAME)




RN 848135-60-4 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]-4-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-65-9 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 848135-67-1 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-68-2 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1-cyclohexyl-4-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 848135-70-6 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-71-7 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 848135-73-9 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-74-0 CAPLUS
 CN 1-Piperazineacetamide, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 848135-76-2 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-78-4 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848135-80-8 CAPLUS
 CN Piperazine, 1-[1,3-benzodioxol-5-yl]-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-82-0 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848135-84-2 CAPLUS
 CN 1-Piperazinecarboxaldehyde, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-86-4 CAPLUS
 CN Piperazine, 1-(3-chlorophenyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 848135-88-6 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-90-0 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 848135-94-4 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848135-98-8 CAPLUS
 CN Piperazine, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-2-methyl-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 848136-03-8 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-05-0 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 848136-07-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-pentyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-09-4 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-propyl- (9CI) (CA INDEX NAME)




RN 848136-11-8 CAPLUS
 CN Piperazine, 1-(cyclopropylmethyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-13-0 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 848136-15-2 CAPLUS
 CN Piperazine, 1-(cyclohexylmethyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-17-4 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 848136-20-9 CAPLUS
CN 1H-1,4-Diazepine, 1-butyl-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-21-0 CAPLUS
CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 848136-22-1 CAPLUS
CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-ethylhexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-23-2 CAPLUS
CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-ethylbutyl)hexahydro- (9CI) (CA INDEX NAME)




RN 848136-24-3 CAPLUS
CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-pentyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 848136-25-4P 848136-26-5P 848136-27-6P
848136-28-7P 848136-29-8P 848136-30-1P
848136-31-2P 848136-32-3P 848136-33-4P
848136-34-5P 848136-35-6P 848136-36-7P
848136-37-8P 848136-38-9P 848136-39-0P
848136-40-3P 848136-41-4P 848136-42-5P
848136-43-6P 848136-44-7P 848136-45-8P
848136-46-9P 848136-47-0P 848136-48-1P
848136-49-2P 848136-50-5P 848136-51-6P
848136-52-7P 848136-53-8P 848136-54-9P
848136-55-0P 848136-56-1P 848136-57-2P
848136-58-3P 848136-59-4P 848136-60-7P
848136-61-8P 848136-62-9P 848136-63-0P
848136-64-1P 848136-65-2P 848136-66-3P
848136-67-4P 848136-68-5P 848136-69-6P
848136-70-9P 848136-71-0P 848136-72-1P
848136-73-2P 848136-74-3P 848136-75-4P
848136-76-5P 848136-77-6P 848136-78-7P
848136-79-8P 848136-80-1P 848136-81-2P
848136-82-3P 848136-83-4P 848136-84-5P
848136-85-6P 848136-86-7P 848136-87-8P
848136-88-9P 848136-89-0P 848136-90-3P
848136-91-4P 848136-92-5P 848136-93-6P
848136-94-7P 848136-95-8P 848136-96-9P
848136-97-0P 848136-98-1P 848136-99-2P
848137-00-8P 848137-01-9P 848137-03-1P
848137-04-2P 848137-05-3P 848137-06-4P
848137-07-5P 848137-08-6P 848137-09-7P
848137-10-0P 848137-11-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phthalazinones as PARP inhibitors for use in the treatment of cancer which is deficient in HR dependent DNA DSB repair pathway)
RN 848136-25-4 CAPLUS
CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-26-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-(cyclopropylmethyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-27-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2,2-dimethylpropyl)hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-28-7 CAPLUS
 CN 1H-1,4-Diazepine, 1-(cyclohexylmethyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-29-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-30-1 CAPLUS
 CN Piperazine, 1-butyl-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 848136-31-2 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-32-3 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 848136-33-4 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-ethylbutyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-34-5 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-pentyl- (9CI) (CA INDEX NAME)




RN 848136-35-6 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-36-7 CAPLUS
 CN Piperazine, 1-(cyclopropylmethyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 848136-37-8 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-38-9 CAPLUS
 CN Piperazine, 1-(cyclohexylmethyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 848136-39-0 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-40-3 CAPLUS
 CN Piperazine, 1-(1-methylethyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 848136-41-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-42-5 CAPLUS
CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(5-isoxazolylcarbonyl)- (9CI) (CA INDEX NAME)




RN 848136-43-6 CAPLUS
CN 1H-1,4-Diazepine, 1-butyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-44-7 CAPLUS
CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 848136-45-8 CAPLUS
CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-ethylhexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-46-9 CAPLUS
CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-ethylbutyl)hexahydro- (9CI) (CA INDEX NAME)




RN 848136-47-0 CAPLUS
CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-48-1 CAPLUS
CN 1H-1,4-Diazepine, 1-(cyclopropylmethyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-49-2 CAPLUS
CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2,2-dimethylpropyl)hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-50-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-(cyclohexylmethyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-51-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(3-methylbutyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-52-7 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(3-furanylmethyl)- (9CI) (CA INDEX NAME)




RN 848136-53-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(3-(methylthio)propyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-54-9 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 848136-55-0 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(1H-pyrrol-2-ylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-56-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-[6,8-dichloro-4-oxo-4H-1-benzopyran-3-yl)methyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-57-2 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-[(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-58-3 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(4-methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 848136-59-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-60-7 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 848136-61-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-(2-benzofuranylmethyl)-4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-62-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 848136-63-0 CAPLUS
 CN Benzoic acid,
 4-[[4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-1H-1,4-diazepin-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-64-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-(2-furanylmethyl)hexahydro- (9CI) (CA INDEX NAME)




RN 848136-65-2 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(4-cyanophenyl)methyl]-4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-66-3 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-(3,7-dimethyl-6-octenyl)hexahydro- (9CI) (CA INDEX NAME)




RN 848136-67-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-68-5 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 848136-69-6 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-70-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(3-methyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 848136-71-0 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(1-methyl-1H-indol-3-yl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-72-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(5-methoxy-1H-indol-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 848136-73-2 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[(2-methoxy-1-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-74-3 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX
 NAME)




RN 848136-75-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(1H-indol-3-ylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-76-5 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX
 NAME)




RN 848136-77-6 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-78-7 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-[[4-(dimethylamino)phenyl]methyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-79-8 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-[(3,5-dimethoxyphenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-80-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 848136-81-2 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-82-3 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-
 4-[(3-fluoro-4-methoxyphenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-83-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-86-7 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[[3-(4-methoxyphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 848136-87-8 CAPLUS
 CN 1H-1,4-Diazepine-1-acetonitrile, 4-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]hexahydro-4-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-84-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-4-[(3,4-dihydro-4-
 oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-85-6 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(1,2-dihydro-6-methoxy-2-oxo-4-pyridinyl)carbonyl]-4-
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI)
 (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-88-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[[4-(trifluoromethyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 848136-89-0 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(1,1'-biphenyl)-4-ylacetyl]-4-[(3,4-dihydro-4-oxo-
 1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-90-3 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxamide, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848136-91-4 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxamide, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-92-5 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxamide, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3,5-dimethylphenyl)hexahydro- (9CI) (CA INDEX NAME)




RN 848136-93-6 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxamide, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(4-ethoxyphenyl)hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-94-7 CAPLUS
 CN Benzoic acid, 4-[[[4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-1H-1,4-diazepin-1-yl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)




RN 848136-95-8 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-96-9 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3-fluorophenyl)hexahydro- (9CI) (CA INDEX NAME)




RN 848136-97-0 CAPLUS
 CN Benzoic acid, 4-[[[4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-1H-1,4-diazepin-1-yl]thioxomethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848136-98-1 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide,
 N-(4-acetylphenyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848136-99-2 CAPLUS
 CN Benzoic acid, 2-[[[4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-1H-1,4-diazepin-1-yl]thioxomethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848137-00-8 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide,
 N-(3-acetylphenyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 848137-01-9 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[4-(dimethylamino)phenyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848137-03-1 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 848137-04-2 CAPLUS
 CN Benzoic acid, 3-[[[4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-1H-1,4-diazepin-1-yl]thioxomethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848137-05-3 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848137-06-4 CAPLUS
 CN Benzoic acid, 2-[[[4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-1H-1,4-diazepin-1-yl]thioxomethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848137-07-5 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(2-trifluoromethylphenyl)- (9CI) (CA INDEX NAME)




RN 848137-08-6 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-fluorophenyl)hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848137-11-1 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




IT 763111-62-2 763111-63-3 763111-64-4
 763111-65-5 763111-66-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of phthalazinones as PARP inhibitors for use in the treatment of cancer which is deficient in HR dependent DNA DSB repair pathway)
 RN 763111-62-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[5-(phenylmethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 848137-09-7 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848137-10-0 CAPLUS
 CN 1H-1,4-Diazepine-1-carbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-63-3 CAPLUS
 CN Piperidine, 4-[3-[(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-64-4 CAPLUS
 CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-65-5 CAPLUS
 CN Piperidine, 4-benzoyl-1-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-66-6 CAPLUS
 CN Piperidine, 1-[3-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 420846-72-6P 763114-26-7P 763114-27-8P
 763114-28-9P 763114-29-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phthalazinones as PARP inhibitors for use in the treatment

of cancer which is deficient in HR dependent DNA DSB repair pathway)
 RN 420846-72-6 CAPLUS
 CN Benzoic acid, 3-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 763114-26-7 CAPLUS
 CN Benzoic acid, 5-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-27-8 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763114-28-9 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763114-29-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-([3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, methyl ester (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004:780675 CAPLUS
 DOCUMENT NUMBER: 141:296034
 TITLE: Preparation of phthalazinones as PARP inhibitors
 INVENTOR(S): Martin, Niall Morrison Barr; Smith, Graeme Cameron
 Murray; Jackson, Stephen Philip; Loh, Vincent M.,
 Jr.;
 Cockcroft, Xiao-Ling Fan; Matthews, Ian Timothy
 Williams; Meneer, Keith Allan; Kerrigan, Frank;
 Ashworth, Alan
 Kudos Pharmaceuticals Limited, UK; Maybridge Limited
 PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080976	A1	20040923	WO 2004-GB1059	20040312
WO 2004080976	C1	20060105		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OH, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220321	A1	20040923	AU 2004-220321	20040312
CA 2517629	AA	20040923	CA 2004-2517629	20040312
GB 2415430	A1	20051228	GB 2005-20754	20040312
GB 2415430	B2	20060712		
BR 2004008284	A	20060307	BR 2004-8284	20040312
EP 1633724	A1	20060315	EP 2004-720068	20040312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1788000	A	20060614	CN 2004-80012878	20040312
JP 2006519827	T2	20060831	JP 2006-505955	20040312
NO 2005004625	A	20051111	NO 2005-4625	20051007
PRIORITY APPLN. INFO.: GB 2003-5681 A 20030312				
US 2003-454995P P 20030314				
US 2003-493399P P 20030806				
US 2003-526244P P 20031201				
WO 2004-GB1059 A 20040312				

OTHER SOURCE(S): MARPAT 141:296034
 GI

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB The title compds. (I: A and B together represent (un)substituted fused aromatic ring; X = NRx or CRxRy; if X = NRx then n = 1 or 2 and if X = CRxRy then n = 1; Rx = H, (un)substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry = H, OH, NH2; or Rx and Ry may together form a spiro(C3-7)cycloalkyl or heterocyclyl group; R1 and R2 are both H, or when X = CRxRy, R1, R2, Rx and Ry, together with the carbon atoms to which they are attached, may form (un)substituted fused aromatic ring; R1 = H, halo), were prepared

Thus, reacting 3-(4-oxo-3,4-dihydrophthalazin-1-ylmethyl)benzoic acid (preparation given) with tert-Bu 1-piperazinecarboxylate afforded 77% II which had IC50 of < 0.02 μ M against PARP. All compds. I tested had a IC50 of < 0.1 μ M in the PARP assay. The pharmaceutical composition comprising the compound I is claimed.


IT 763111-46-2P 763111-47-3P 763111-48-4P 763111-49-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of phthalazinones as PARP inhibitors)

RN 763111-46-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 763111-47-3 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 763111-48-4 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 763111-49-5 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)




IT 763111-50-8P 763111-51-9P 763111-52-0P
 763111-53-1P 763111-54-2P 763111-55-3P
 763111-56-4P 763111-57-5P 763111-58-6P
 763111-59-7P 763111-60-0P 763111-61-1P
 763111-62-2P 763111-63-3P 763111-64-4P
 763111-65-5P 763111-66-6P 763111-67-7P
 763111-68-8P 763111-69-9P 763111-70-2P
 763111-71-3P 763111-72-4P 763111-73-5P
 763111-74-6P 763111-75-7P 763111-76-8P
 763111-77-9P 763111-78-0P 763111-79-1P
 763111-80-4P 763111-81-5P 763111-82-6P
 763111-83-7P 763111-85-9P 763111-87-1P
 763111-89-3P 763111-91-7P 763111-92-8P
 763111-93-9P 763111-94-0P 763111-95-1P
 763111-96-2P 763111-97-3P 763111-98-4P
 763111-99-5P 763112-00-1P 763112-01-2P
 763112-02-3P 763112-03-4P 763112-04-5P
 763112-05-6P 763112-06-7P 763112-07-8P
 763112-08-9P 763112-09-0P 763112-10-3P

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


763112-11-4P 763112-12-5P 763112-13-6P
 763112-14-7P 763112-15-8P 763112-16-9P
 763112-17-0P 763112-18-1P 763112-19-2P
 763112-20-5P 763112-21-6P 763112-22-7P
 763112-23-8P 763112-24-9P 763112-25-0P
 763112-26-1P 763112-27-2P 763112-28-3P
 763112-29-4P 763112-30-5P 763112-31-6P
 763112-32-7P 763112-33-8P 763112-34-9P
 763112-35-0P 763112-36-1P 763112-37-2P
 763112-38-3P 763112-39-4P 763112-40-5P
 763112-41-6P 763112-42-7P 763112-43-8P
 763112-44-9P 763112-45-0P 763112-46-1P
 763112-47-2P 763112-48-3P 763112-49-4P
 763112-50-5P 763112-51-6P 763112-52-7P
 763112-53-8P 763112-54-9P 763112-55-0P
 763112-56-1P 763112-57-2P 763112-58-3P
 763112-59-4P 763112-60-5P 763112-61-6P
 763112-62-7P 763112-63-8P 763112-64-9P
 763112-65-0P 763112-66-1P 763112-67-2P
 763112-68-3P 763112-69-4P 763112-70-5P
 763112-71-6P 763112-72-7P 763112-73-8P
 763112-74-9P 763112-75-0P 763112-76-1P
 763112-77-2P 763112-78-3P 763112-79-4P
 763112-80-5P 763112-81-6P 763112-82-7P
 763112-83-8P 763112-84-9P 763112-85-0P
 763112-86-1P 763112-87-2P 763112-88-3P
 763112-89-4P 763112-90-5P 763112-91-6P
 763112-92-7P 763112-93-8P 763112-94-9P
 763112-95-0P 763112-96-1P 763112-97-2P
 763112-98-3P 763112-99-4P 763113-00-5P
 763113-01-6P 763113-02-7P 763113-03-8P
 763113-04-9P 763113-05-0P 763113-06-1P
 763113-07-2P 763113-08-3P 763113-09-4P
 763113-10-5P 763113-11-6P 763113-12-7P
 763113-13-8P 763113-14-9P 763113-15-0P
 763113-16-1P 763113-17-2P 763113-18-3P
 763113-19-4P 763113-20-5P 763113-21-6P
 763113-22-7P 763113-23-8P 763113-24-9P
 763113-25-0P 763113-26-1P 763113-27-2P
 763113-28-3P 763113-29-4P 763113-30-5P
 763113-31-6P 763113-32-7P 763113-33-8P
 763113-34-9P 763113-35-0P 763113-36-1P
 763113-37-2P 763113-38-3P 763113-39-4P
 763113-40-5P 763113-41-6P 763113-42-7P
 763113-43-8P 763113-44-9P 763113-45-0P
 763113-46-1P 763113-47-2P 763113-48-3P
 763113-49-4P 763113-50-5P 763113-51-6P
 763113-52-7P 763113-53-8P 763113-54-9P
 763113-55-0P 763113-56-1P 763113-57-2P
 763113-58-3P 763113-59-4P 763113-60-5P
 763113-61-6P 763113-62-7P 763113-63-8P
 763113-64-9P 763113-65-0P 763113-66-1P
 763113-67-2P 763113-68-3P 763113-69-4P
 763113-70-5P 763113-71-6P 763113-72-7P
 763113-73-8P 763113-74-9P 763113-75-0P
 763113-76-1P 763113-77-2P 763113-78-3P
 763113-79-4P 763113-80-5P 763113-81-6P
 763113-82-7P

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

763113-83-8P 763113-84-9P 763113-85-0P
 763113-86-1P 763113-87-2P 763113-88-3P
 763113-89-4P 763113-90-5P 763113-91-6P
 763113-92-7P 763113-93-8P 763113-94-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of phthalazinones as PARP inhibitors)
 RN 763111-50-8 CAPLUS
 CN 1H-1,4-Diazepine,
 1-(6-chloro-2-benzothiazolyl)-4-[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763111-51-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 763111-52-0 CAPLUS

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-1,4-Diazepine,
 1-[(4-bromo-2-fluorophenyl)methyl]-4-[3-[(3,4-dihydro-4-
 oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763111-53-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 763111-54-2 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[5-propyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-55-3 CAPLUS
 CN 1H-1,4-Diazepine, 1-(3-cyano-2-pyridinyl)-4-[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763111-56-4 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-[(3,4-dihydro-4-oxo-1-
 phthalazinyl)methyl]benzoyl]hexahydro-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-57-5 CAPLUS
CN 1H-1,4-Diazepine-1-ethanol, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763111-58-6 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-59-7 CAPLUS
CN Piperazine, 1-(5-cyano-2-pyridinyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-60-0 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-61-1 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[5-nitrobenzoyl]- (9CI) (CA INDEX NAME)




RN 763111-62-2 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[5-(phenylmethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-63-3 CAPLUS
CN Piperidine, 4-[3-[(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-64-4 CAPLUS
CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-65-5 CAPLUS
 CN Piperidine, 4-benzoyl-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763111-67-7 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 763111-66-6 CAPLUS
 CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 763111-68-8 CAPLUS
 CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-69-9 CAPLUS
 CN Piperidine, 4-(4-chlorobenzoyl)-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-70-2 CAPLUS
 CN Spiro[piperidine-4,1'-[1H]pyrido[3,4-b]indole], 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-2',3',4',9'-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-71-3 CAPLUS
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-72-4 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[2,6-dinitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-73-5 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-phenyl-1,2,4-thiadiazol-5-yl)- (9CI) (CA INDEX NAME)




RN 763111-74-6 CAPLUS
 CN Piperazine, 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-75-7 CAPLUS
 CN Piperazine, 1-(5-chloro-1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-76-8 CAPLUS
 CN Piperazine, 1-(cyclohexylcarbonyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-77-9 CAPLUS
 CN 3-Thiophenecarboxylic acid, 5-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 763111-78-0 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(3-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-79-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(2-nitro-4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 763111-80-4 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-81-5 CAPLUS
 CN 1,3-Dioxolo[4,5-g]isoquinoline, 6-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 763111-82-6 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-83-7 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 763111-85-9 CAPLUS
 CN Piperidine,
 1-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidiny]carbonyl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-87-1 CAPLUS
 CN Piperidine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-methyl-1-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 763111-89-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763111-91-7 CAPLUS
 CN Isoquinoline,
 2-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidiny]carbonyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 763111-92-8 CAPLUS
 CN Isoquinoline,
 2-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidiny]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763111-93-9 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(4-(1,1-dimethylethyl)cyclohexyl)- (9CI) (CA INDEX NAME)




RN 763111-94-0 CAPLUS
 CN Piperidine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 763111-95-1 CAPLUS
 CN 4-Piperidinecarboxamide, N-[(1S)-2,3-dihydro-1H-inden-1-yl]-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-96-2 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 763111-97-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763111-98-4 CAPLUS
 CN 4-Piperidinecarboxamide, N-(cyclohexylmethyl)-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763111-99-5 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-00-1 CAPLUS
 CN 4-Piperidinecarboxamide, N-(cyclopropylmethyl)-1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-01-2 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methylcyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-02-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N,N-di-2-propenyl- (9CI) (CA INDEX NAME)




RN 763112-03-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[1-ethynylcyclohexyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-04-5 CAPLUS
 CN 4-Piperidinecarboxamide, N-cyclopentyl-1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-05-6 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[(2S)-2-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-06-7 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-[[[1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 763112-07-8 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-08-9 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 763112-09-0 CAPLUS
 CN Piperazine, 1-bis(4-fluorophenyl)methyl]-4-[[1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-10-3 CAPLUS
 CN Piperazine,
 1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 763112-11-4 CAPLUS
 CN Piperazine,
 1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-14-7 CAPLUS
 CN Piperazine,
 1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 763112-15-8 CAPLUS
 CN Piperazine, 1-(4-acetylphenyl)-4-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-12-5 CAPLUS
 CN Piperazine,
 1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 763112-13-6 CAPLUS
 CN Piperazine, 1-(4-chlorophenyl)-4-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-16-9 CAPLUS
 CN Piperazine,
 1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 763112-17-0 CAPLUS
 CN Piperazine,
 1-([1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl)-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-18-1 CAPLUS
CN Piperazine, 4-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]-2-methyl-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 763112-19-2 CAPLUS
CN Piperazine, 1-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-20-5 CAPLUS
CN Piperazine, 1-cyclohexyl-4-[[1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-21-6 CAPLUS
CN Morpholine, 4-[[1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-22-7 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 763112-23-8 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(ethylsulfonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-24-9 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 763112-25-0 CAPLUS
CN Piperazine, 1-[(2-chlorophenyl)sulfonyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-26-1 CAPLUS
 CN Piperazine,
 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl- (9CI) (CA INDEX NAME)




RN 763112-27-2 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-29-4 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 763112-31-8 CAPLUS
 CN Piperazine, 1-[(butylsulfonyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-32-9 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763112-34-1 CAPLUS
 CN 1H-1,4-Diazepine, 1-(butylsulfonyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-35-2 CAPLUS
 CN Piperazine, 1-[(1,1'-biphenyl)-4-ylcarbonyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl- (9CI) (CA INDEX NAME)




RN 763112-37-4 CAPLUS
 CN Piperazine, 1-(2-chloro-4-fluorobenzoyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-39-6 CAPLUS
 CN Piperazine, 1-[(acetyloxy)acetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-40-9 CAPLUS
 CN Piperazine, 1-[2-(acetyloxy)-2-methyl-1-oxopropyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-42-1 CAPLUS
 CN Piperazine, 1-[(acetyloxy)phenylacetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-43-2 CAPLUS
 CN Piperazine, 1-[(acetyloxy)phenylacetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-44-3 CAPLUS
 CN 1-Piperazinepropanoic acid, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 763112-45-4 CAPLUS
 CN Piperazine, 1-[(2,5-dimethyl-3-furanylcarbonyl)- (9CI) (CA INDEX NAME)]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-46-5 CAPLUS
 CN Piperazine, 1-[(2-oxo-2-phenylpropanoyl)acetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-47-6 CAPLUS
 CN Piperazine, 1-[(2-oxo-2-phenylpropanoyl)acetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-48-7 CAPLUS
 CN Piperazine, 1-[(2,1,3-benzothiadiazol-5-ylcarbonyl)-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)




RN 763112-49-8 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-50-1 CAPLUS
 CN Piperazine, 1-[(2-[(benzoyloxy)methyl]benzoyl)-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)




RN 763112-51-2 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-52-3 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)




RN 763112-53-4 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-54-5 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)




RN 763112-55-6 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-{3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl}]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-56-7 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-4-chlorophenyl)cyclopropyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-57-8 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1H-indol-1-yl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-58-9 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(5-isoxazolyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-59-0 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2-benzothiazolylthio)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-60-3 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-61-4 CAPLUS
 CN Piperazine,
 1-[[4-[(1,2-dihydro-2-methyl-1-oxo-3-isoquinolinyl)-1-oxobutyl]-3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763112-62-5 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-63-6 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2,4,6-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 763112-64-7 CAPLUS

CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-methoxyphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 763112-65-8 CAPLUS


CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 763112-66-9 CAPLUS


CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-thienylacetyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763112-69-2 CAPLUS


CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-ethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 763112-70-5 CAPLUS


CN Piperazine, 1-[(1,1'-biphenyl)-4-ylacetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763112-67-0 CAPLUS


CN Piperazine, 1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 763112-68-1 CAPLUS


CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-methyl-1-oxoheptyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763112-71-6 CAPLUS


CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-fluorophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-72-7 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-73-8 CAPLUS
 CN Piperazine, 1-[(3-benzodioxol-5-ylacetyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-74-9 CAPLUS
 CN Piperazine, 1-[(3-(3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-4-(3-thienylacetyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-75-0 CAPLUS
 CN Piperazine, 1-[(3,5-difluorophenyl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763112-76-1 CAPLUS
 CN Piperazine, 1-[(2,3-dihydro-1H-inden-2-yl)acetyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-77-2 CAPLUS
 CN Piperazine, 1-[(3-(3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-4-[(3-(4-fluorophenyl)-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 763112-78-3 CAPLUS
 CN Piperazine, 1-[(4-butoxyphenyl)acetyl]-4-[(3-(3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-79-4 CAPLUS
 CN Piperazine, 1-[(3-(3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-4-[(3-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-80-7 CAPLUS
 CN Piperazine, 1-[(3-(3,4-dihydro-4-oxo-1-phthalazinyl)methyl)benzoyl]-4-(phenylacetyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-81-8 CAPLUS
 CN Piperazine,
 1-[(4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-1,4-dioxobutyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)]




RN 763112-82-9 CAPLUS
 CN Piperazine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[(5-methyl-2-phenyl-4-oxazolyl)acetyl]- (9CI) (CA INDEX NAME)]

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-83-0 CAPLUS
 CN Piperazine, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)acetyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)]




RN 763112-84-1 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3S)-1-oxo-3-phenylbutyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-85-2 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)]




RN 763112-86-3 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(2-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)]

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-87-4 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3-fluorophenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)]




RN 763112-88-5 CAPLUS
 CN Piperazine, 1-[(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)-4-[(3-methylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)]

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-89-6 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(2-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-90-9 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-91-0 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(3-fluorophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 763112-92-1 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-93-2 CAPLUS
 CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1,3-dimethyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-94-3 CAPLUS
 CN Piperazine,
 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-95-4 CAPLUS
 CN Piperazine,
 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-3-phenyl-1H-thieno[2,3-c]pyrazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-96-5 CAPLUS
 CN Piperazine,
 1-[(1-(4-(4-chlorophenyl)-2-thiazolyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbonyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-97-6 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[2-phenyl-4-(trifluoromethyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763112-98-7 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[3-methyl-2-(2-thienyl)-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763112-99-8 CAPLUS
 CN Piperazine,
 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[4-methyl-2-phenyl-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 763113-00-4 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[3-(2-methylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-01-5 CAPLUS
 CN Piperazine, 1-benzoyl-4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-02-6 CAPLUS
 CN 1-Piperazinepropanoic acid, 4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-oxo-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-03-7 CAPLUS
 CN Piperazine, 1-(cyclopentylcarbonyl)-4-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-04-8 CAPLUS
 CN Piperazine, 1-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[[3-(2-methylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-05-9 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1R,2R)-2-phenylcyclopropyl]carbonyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 763113-06-0 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-07-1 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 763113-08-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-quinoxaliny carbonyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763113-09-3 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 763113-10-6 CAPLUS
 CN Piperazine, 1-(benzo[b]thien-2-ylcarbonyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763113-11-7 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 763113-12-8 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763113-13-9 CAPLUS
 CN Piperazine, 1-(2,4-difluorobenzoyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-14-0 CAPLUS
 CN Piperazine, 1-(2-chlorobenzoyl)-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763113-16-2 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 763113-15-1 CAPLUS
 CN Piperazine, 1-[3,4-dichlorobenzoyl]-4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl)- (9CI) (CA INDEX NAME)




RN 763113-17-3 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-methylbenzoyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-18-4 CAPLUS
 CN Morpholine, 4-[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763113-20-8 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 763113-19-5 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 763113-21-9 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[(1-methyl-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-22-0 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 763113-23-1 CAPLUS
 CN Morpholine, 4-[[4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-24-2 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[3-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763113-25-3 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[3-(hexahydro-1H-1,4-diazepin-1-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-26-4 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-[3-(4-methyl-1-piperazinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763113-27-5 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-28-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(1-oxo-2-propynyl)- (9CI) (CA INDEX NAME)




RN 763113-29-7 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-[(4-phenylbicyclo[1.1.1]pent-2-yl)carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-30-0 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(1-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 763113-31-1 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(2-methyl-1-oxo-2-pentenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-34-4 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(2-methyl-1-oxoheptyl)- (9CI) (CA INDEX NAME)




RN 763113-35-5 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[(2-chloro-6-methoxy-4-pyridinyl)carbonyl]-4-[3-[(3,4-
 dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro- (9CI) (CA INDEX
 NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-32-2 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-33-3 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-(5-isoxazolylcarbonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-36-6 CAPLUS
 CN 1H-1,4-Diazepine,
 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]h
 exahydro-4-[3-(3-methoxyphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 763113-37-7 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-
 fluorobenzoyl]-4-[(dimethylamino)acetyl]hexahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-38-8 CAPLUS
 CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 763113-39-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-40-2 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 763113-41-3 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-42-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 763113-43-5 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763113-44-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 763113-45-7 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763113-46-8 CAPLUS
 CN 1-Piperazinecarboxamide, N-(2,4-difluorophenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-47-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 763113-48-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-ethylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-49-1 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 763113-50-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-51-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-(3-cyanophenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-52-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-53-7 CAPLUS
 CN 1-Piperazinecarboxamide, N-cyclohexyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-54-8 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-55-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 763113-56-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-57-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-[(2-chlorophenyl)methyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-58-2 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-59-3 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 763113-60-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-62-8 CAPLUS
 CN 1-Piperazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-63-9 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[1-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-64-0 CAPLUS
 CN L-Valine, N-[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 763113-65-1 CAPLUS
 CN 1-Piperazinecarboxamide, N-benzoyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-66-2 CAPLUS
 CN 1-Piperazinecarboxamide, N-[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 763113-67-3 CAPLUS
 CN Benzoic acid, 3-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-68-4 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 763113-69-5 CAPLUS
 CN Benzoic acid, 2-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-70-8 CAPLUS
 CN Benzoic acid, 3-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 763113-71-9 CAPLUS
 CN Benzoic acid, 4-[[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-72-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinyl]carbonylamino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 763113-73-1 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-74-2 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 763113-75-3 CAPLUS
 CN 1-Piperazinecarbothioamide, N-butyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-76-4 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 763113-77-5 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(pentafluorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-78-6 CAPLUS
 CN Benzoic acid, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinylthioxomethylamino]-, methyl ester (9CI) (CA INDEX NAME)




RN 763113-79-7 CAPLUS
 CN Benzoic acid, 2-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1-piperazinylthioxomethylamino]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-80-0 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(3-acetylphenyl)- (9CI) (CA INDEX NAME)




RN 763113-81-1 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-82-2 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 763113-83-3 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-84-4 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 763113-85-5 CAPLUS
 CN 1-Piperazinecarbothioamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-86-6 CAPLUS
 CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 763113-87-7 CAPLUS
 CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-88-8 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 763113-89-9 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-92-4 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 763113-93-5 CAPLUS
CN 1-Piperazineacetamide, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-90-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 763113-91-3 CAPLUS
CN Piperazine, 1-cyclohexyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-94-6 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




IT 763113-95-7P 763113-96-8P 763113-97-9P
763113-98-0P 763113-99-1P 763114-00-7P
763114-01-8P 763114-02-9P 763114-03-0P
763114-04-1P 763114-05-2P 763114-06-3P
763114-07-4P 763114-08-5P 763114-09-6P
763114-10-9P 763114-11-0P 763114-12-1P
763114-13-2P 763114-14-3P 763114-15-4P
763114-16-5P 763114-17-6P 763114-18-7P
763114-19-8P 763114-20-1P 763114-21-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phthalazinones as PARP inhibitors)
RN 763113-95-7 CAPLUS
CN Piperazine, 1-(4-acetylphenyl)-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-96-8 CAPLUS
CN Piperazine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 763113-97-9 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763113-98-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 763113-99-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 763114-00-7 CAPLUS
CN Isoquinoline, 2-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 763114-01-8 CAPLUS
CN 1H-1,4-Diazepine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 763114-02-9 CAPLUS
CN 1H-1,4-Diazepine-1-ethanol, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]hexahydro- (9CI) (CA INDEX NAME)




RN 763114-03-0 CAPLUS
CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 763114-04-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-05-2 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 763114-06-3 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-07-4 CAPLUS
 CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 763114-08-5 CAPLUS
 CN Morpholine, 4-[4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1-piperazinyl]acetyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-09-6 CAPLUS
 CN 1-Piperazineethanol, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)




RN 763114-10-9 CAPLUS
 CN 1-Piperazineethanamine, 4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-11-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 763114-12-1 CAPLUS
 CN Isoquinoline, 2-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-13-2 CAPLUS
CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 763114-14-3 CAPLUS
CN Piperazine, 1-butyl-4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-15-4 CAPLUS
CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 763114-16-5 CAPLUS
CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-[(1-methyl-1H-indol-3-yl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-17-6 CAPLUS
CN Piperazine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]-4-(1H-indol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 763114-18-7 CAPLUS
CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-19-8 CAPLUS
CN Piperazine, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-4-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 763114-20-1 CAPLUS
CN 1H-1,4-Diazepine, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]hexahydro-4-(1-methylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-21-2 CAPLUS
 CN 1H-1,4-Diazepine, 1-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoylhexahydro-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 420846-72-6P 763114-26-7P 763114-27-8P
 763114-28-9P 763114-29-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phthalazinones as PARP inhibitors)
 RN 420846-72-6 CAPLUS
 CN Benzoic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-26-7 CAPLUS
 CN Benzoic acid, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 763114-27-8 CAPLUS
 CN 4-piperidinecarboxylic acid, 1-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 763114-28-9 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]- (9CI) (CA INDEX NAME)



RN 763114-29-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:263255 CAPLUS

DOCUMENT NUMBER: 141:277582


TITLE: A convenient synthesis of 4-diarylmethyl-, 4-(α -hydroxy- α -aryl/naphthyl)methyl- and 4-(benzoyl/naphthanoyl)-1-(2H)-phthalazinones from ninhydrin

AUTHOR(S): Kundu, Sandip Kumar; Pramanik, Animesh
CORPORATE SOURCE: Department of Chemistry, Calcutta University, Kolkata,

SOURCE: 700 009, India
Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2004), 43B(3), 595-603

PUBLISHER: CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: National Institute of Science Communication
LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:277582
GI



I

AB Refluxing of 2,2-diaryl-1,3-indanediones in hydrazine hydrate for a brief period affords 4-diarylmethyl-1-(2H)-phthalazinones, e.g. I, in very high yield. A series of 4-(α -hydroxy- α -aryl/naphthyl)methyl- and 4-(benzoyl/naphthanoyl)-1-(2H)-phthalazinones also have been synthesized via ring cleavage and cyclization of 2-hydroxy-2-aryl/naphthyl-1,3-dioxindanes in hydrazine hydrate (99%) at room temperature in very high yields.


All the ninhydrin adducts, 2,2-diaryl-1,3-indanediones and 2-hydroxy-2-aryl/naphthyl-1,3-dioxindanes are prepared by stirring ninhydrin and the appropriate aromatic hydrocarbons in acid medium.

IT 758720-62-6P 758720-63-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(synthesis of 4-diarylmethyl-, 4-(α -hydroxy- α -aryl/naphthyl)methyl- and 4-(benzoyl/naphthanoyl)-1-(2H)-phthalazinones from ninhydrin via ring cleavage and cyclization reactions)

RN 758720-62-6 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(2,5-dimethoxyphenyl)hydroxymethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 758720-63-7 CAPLUS
CN 1(2H)-Phthalazinone, 4-[hydroxy(2,3,4-trimethoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)




IT 465498-69-5P 758720-67-1P 758720-68-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 4-diarylmethyl-, 4-(α -hydroxy- α -aryl/naphthyl)methyl- and 4-(benzoyl/naphthanoyl)-1-(2H)-phthalazinones from ninhydrin via ring cleavage and cyclization reactions)
RN 465498-69-5 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(4-methoxyphenyl)(2,3,4-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 758720-67-1 CAPLUS
CN 1(2H)-Phthalazinone, 4-(2-hydroxy-3-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 758720-68-2 CAPLUS
CN 1(2H)-Phthalazinone, 4-(2-hydroxy-5-methylbenzoyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:892770 CAPLUS
 DOCUMENT NUMBER: 139:381498
 TITLE: Phthalazinone derivatives useful as inhibitors of

PARP

(i.e., poly(ADP-ribose) polymerase) and their preparation, pharmaceutical compositions, and use, e.g., as potentiators in the treatment of cancer

INVENTOR(S): Martin, Niall; Morrison Barr, Smith, Graeme; Cameron Murray, Eversley, Penny; Jane, Cockcroft, Xiao-Ling Fan; Kerrigan, Frank; Hoare, Janet; Dixon, Lesley

PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; Maybridge PLC

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093261	A1	20031113	WO 2003-GB1817	20030429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482806	AA	20031113	CA 2003-2482806	20030429
AU 2003229953	A1	20031117	AU 2003-229953	20030429
US 2004023968	A1	20040205	US 2003-426147	20030429
EP 1501822	A1	20050202	EP 2003-722792	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200609719	T2	20060323	JP 2004-501400	20030429
PRIORITY APPLN. INFO.:			US 2002-376497P	P 20020430
			WO 2003-GB1817	W 20030429

OTHER SOURCE(S): MARPAT 139:381498
 GI

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I and their isomers, salts, solvates, chemical protected forms,

and prodrugs thereof, are useful as pharmaceuticals, in particular, for the treatment of diseases ameliorated by inhibiting the activity of PARP, i.e., poly(ADP-ribose) polymerase [wherein: A and B together = optionally substituted, fused aromatic ring; R1 = C5-7 aryl group substituted in the meta position by the group R2, and optionally further substituted; R2 =

5- or 6-membered lactams or cyclic ureas, bound at the amide N, or 5- or 6-membered cyclic imides, including piperazine-2,6-diones, bound at the imide N]. I are claimed as useful for therapy, in human or animals, and particularly for 3 cases: (1) inhibiting the activity of PARP, preferably to maximize DNA repair inhibition; (2) in treatment of a variety of disorders, including cardiovascular conditions, ischemia, neurotoxicity, and inflammation; and (3) as an adjunct in cancer therapy, or for potentiating tumor cells for treatment with ionizing radiation or chemotherapeutics. Examples include 43 preps. of specific compds. I. For instance, phthalide was cyclocondensed with 3-nitrobenzaldehyde to give 2-(3-nitrophenyl)indan-1,3-dione, which was re-cyclized with hydrazine to give 4-(3-aminobenzyl)-2H-phthalazin-1-one. This amine was cyclized with succinic anhydride in refluxing acetic acid to give invention compound II, a preferred compound. In a test for inhibition of

HeLa cellular PARP in vitro, II had an IC50 value of < 0.03 μM, vs. 7.2 μM for the base structure, 1(2H)-phthalazinone. In a test for potentiation of the alkylating agent Me methanesulfonate (MMS) against HeLa cells in vitro, several compds., including II, had potentiating factors (PF50) of 21 at 200 nM.


IT 420846-57-7P, 4-(3-Aminobenzyl)-2H-phthalazin-1-one 623577-82-2P, 4-Chloro-N-[3-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]butyramide 623577-97-9P, N-[3-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-2-phenylsuccinamic acid 623577-98-0P, N-[3-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-3-phenylsuccinamic acid 623578-09-6P, 4-(3-Amino-4-fluorobenzyl)-2H-phthalazin-1-one 623578-10-9P, N-[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]succinamic acid 623578-12-1P, 4-[[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]butyric acid 623578-14-3P, N-[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-2-phenylsuccinamic acid 623578-16-5P, N-[2-Fluoro-5-[(4-oxo-3,4-

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dihydrophthalazin-1-yl)methyl]phenyl]-2,2-dimethylsuccinamic acid 623578-18-7P, 2-[[[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]cyclopropanecarboxylic acid 623578-21-2P, 2-[[[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]methyl]dec-4-enoic acid 623578-23-4P, 2-[[[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]methyl]oct-4-enoic acid 623578-28-9P, 2-Benzyl-N-[2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]succinamic acid 623578-30-3P, N-[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-2-methylsuccinamic acid 623578-32-5P, (S)-3-

[[(Benzyloxy)carbonyl]amino]-N-[2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]succinamic acid benzyl ester 623578-33-6P, (S)-3-[[(Benzyloxy)carbonyl]amino]-N-[2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]succinamic acid 623578-35-8P, N-[[[2-Fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]methyl]-N-methylglycine 623578-40-5P, 4-(3-Amino-4-chlorobenzyl)-2H-phthalazin-1-one 623578-41-6P, N-[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]succinamic acid 623578-43-8P, N-[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-2-phenylsuccinamic acid 623578-44-9P, N-[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-3-phenylsuccinamic acid 623578-46-1P, N-[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-2-(hexen-2-yl)succinamic acid 623578-47-2P, N-[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]-3-(hexen-2-yl)succinamic acid 623578-49-4P, 2-[[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]cyclopropanecarboxylic acid 623578-51-8P, 4-[[2-Chloro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]carbamoyl]butyric acid 623578-55-2P, 4-(3-Amino-4-methoxybenzyl)-2H-phthalazin-1-one 623578-56-3P,


N-[2-Methoxy-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]phenyl]succinamic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate) prepn. of phthalazinone derivs. as PARP inhibitors)

RN 420846-57-7 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3-aminophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 623577-82-2 CAPLUS

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Butanamide, 4-chloro-N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 623577-97-9 CAPLUS
 CN Benzenecarboxylic acid, u-[2-[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 623577-98-0 CAPLUS
 CN Benzenepropanoic acid, β-[[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-09-6 CAPLUS
CN 1-(2H)-Phthalazinone, 4-[(3-amino-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 623578-10-9 CAPLUS
CN Butanoic acid, 4-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-12-1 CAPLUS
CN Pentanoic acid, 5-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)




RN 623578-14-3 CAPLUS
CN Benzeneacetic acid, alpha-[2-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-16-5 CAPLUS
CN Butanoic acid, 4-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2,2-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 623578-18-7 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-21-2 CAPLUS
CN 4-Decenoic acid, 2-[2-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 623578-23-4 CAPLUS
CN 4-Octenoic acid, 2-[2-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-28-9 CAPLUS
 CN Benzenepropanoic acid, α -[2-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 623578-30-3 CAPLUS
 CN Butanoic acid, 4-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2-methyl-4-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 623578-32-5 CAPLUS
 CN Butanoic acid, 4-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-4-oxo-3-[[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 623578-33-6 CAPLUS
 CN Butanoic acid, 4-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-4-oxo-3-[[[(phenylmethoxy)carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-35-8 CAPLUS
 CN Glycine, N-[2-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]amino]-2-oxoethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 623578-40-5 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3-amino-4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-41-6 CAPLUS
 CN Butanoic acid, 4-[[2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 623578-43-8 CAPLUS
 CN Benzenepropanoic acid, α -[2-[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-44-9 CAPLUS
 CN Benzenepropanoic acid, β -[[[2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 623578-46-1 CAPLUS
 CN 4-Octenoic acid, 2-[2-[[[2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-47-2 CAPLUS
 CN 5-Nonenoic acid, 3-[[[2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 623578-49-4 CAPLUS
 CN 2-Cyclopropanecarboxylic acid, 2-[[[2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 623578-51-8 CAPLUS
 CN Pentanoic acid, 5-[[[2-chloro-5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)




RN 623578-55-2 CAPLUS
 CN 1-(2H)-Phthalazinone, 4-[[[3-amino-4-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 623578-56-3 CAPLUS
 CN Butanoic acid, 4-[[[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-methoxyphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:678790 CAPLUS
 DOCUMENT NUMBER: 139:214477
 TITLE: Preparation of fused pyridazine derivatives as poly(ADP-ribose)polymerase inhibitors
 INVENTOR(S): Seko, Takuya; Takeuchi, Jun; Takahashi, Shinya; Kamanaka, Yoshihisa; Kamoshima, Wataru
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 368 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070707	A1	20030828	WO 2003-JP1694	20030218
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476406	AA	20030828	CA 2003-2476406	20030218
AU 2003211381	A1	20030909	AU 2003-211381	20030218
EP 1477175	A1	20041117	EP 2003-705265	20030218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007780	A	20041228	BR 2003-7780	20030218
US 2005085476	A1	20050421	US 2003-505912	20030218
CN 1646499	A	20050727	CN 2003-808459	20030218
ZA 200406507	A	20050221	ZA 2004-6507	20040816
NO 200403429	A	20041119	NO 2004-3429	20040817
PRIORITY APPLN. INFO.:			JP 2002-42259	A 20020219
			JP 2002-199673	A 20020709
			WO 2003-JP1694	W 20030218


OTHER SOURCE(S): MARPAT 139:214477
 GI

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 one (II) as an oil. SOC12 (5.20 mL) was added dropwise to 20.0 mL MeOH at -10°, stirred at 0° for 15 min, treated with II, stirred at room temp. for 18 h, concd., dissolved in 20 mL CH2Cl2, treated with Et3N, treated with H2O, and extd. with CH2Cl2 to give, after workup and silica gel chromatog., 3-(3-aminophenyl)-3-methoxy-4,5,6,7-tetrahydro-2-benzofuran-1(3H)-one (III). A soln. of 2.56 g III and 503 mg hydrazine monohydrate in 30.0 mL EtOH was refluxed for 18 h, cooled to room temp., and filtered to give, after washing the crystals obtained with hexane and drying, 32.0 mg 4-(3-aminophenyl)-5,6,7,8-tetrahydropthalazine-1(2H)-one. 4-(3,5-Diaminophenyl)-6,7,9,9a-tetrahydro[1,4]thiazino[4,3-d][1,2,4]triazin-1(2H)-one 8-(3-aminophenyl)-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one mono- or dihydrochloride, and 4-[N-(2-aminoethyl)carbamoylmethyl]-5,6,7,8-tetrahydropthalazin-1(2H)-one (IV) showed IC50 of 0.61, 0.10, and 0.29 µg/mL, resp. against poly(ADP-ribose)polymerase. A tablet and an ampule formulation contg. IV were described.
 IT 590408-00-7P 590408-03-0P 590408-04-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused pyridazine derivs. as poly(ADP-ribose)polymerase inhibitors for treatment or prevention of diseases such as ischemia, inflammations and neurodegenerative diseases)
 RN 590408-00-7 CAPLUS
 CN 1(2H)-Phthalazinone, 5,6,7,8-tetrahydro-4-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 590408-03-0 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3-aminophenyl)methyl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB The title compds. (I) and pharmaceutically acceptable salts thereof [R1 = H, Cl-8 alkyl, Cl-8 alkoxy, HO, halo, NO2, each optionally N-mono- or dialkylated NH2 or amino-C2-8 acyl, C2-8 acyl, phenyl-Cl-8 alkoxy; X, Y = C, CH, N; a solid line accompanied by a dotted line is a single or double bond; the ring Z containing X and Y = each partially or completely saturated C3-10 monocyclic carbocyclic aryl or 3- to 10-membered monocyclic heterocyclic aryl containing 1-4 heteroatoms selected from O, N, and S; A = Q, Q1, Q2, Q3, etc.; wherein D1 = each N-(un)substituted NHCO, NHC(S), NHSO2, CH2NH, CH2NHCO, NHCONH, NH, NHCO2, NHC(S)NH, NH, or NHC(:NH), CH2O, OC(O); D2 = Cl-8 alkylene, C2-8 alkenylene, Cyc2, -(Cl-4 alkylene)-O-(Cl-4 alkylene)-, -(Cl-4 alkylene)-S-(Cl-4 alkylene)-, -(Cl-4 alkylene)-NH-(Cl-4 alkylene)-, etc.; D3 = H, Cyc3, each (un)substituted NH2, CONH2, C(:CH)NH2, or NHC(:NH)NH2, OH, alkoxy, CO2H, alkoxycarbonyl, cyano, halo; G1 = Cl-8 alkylene; G2 = H, Cl-8 alkyl, Cl-8 alkoxy, C2-8 acyl, Cyc6, NO2, Cyc6-Cl-8 alkoxycarbonyl, -CO-Cyc6, etc.; R5 = H, Cl-8 alkyl, Cl-8 alkoxy, HO, NO2, each N-(un)substituted NH2 or amino-Cl-8 alkyl, NHSO2OH, amidino, etc.; Cyc1, Cyc2, Cyc3, Cyc5, Cyc6 = groups each partially or completely saturated and monocyclic or bicyclic C3-10 carbocyclic aryl or 3- to 10-membered heterocyclic aryl containing 1-4 heteroatoms selected from O, N, and S] are prepared Because of inhibiting poly(ADP-ribose)polymerase, the compds. I are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebroclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), cataract, diabetes, diabetes complications, shock, head trauma, spinal cord injury, renal failure, and hyperalgesia. Moreover, these compds. are useful as agents against retroviruses (HIV, etc.) and sensitizers in treating cancer and immunosuppressants. Thus, a solution of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride in THF (1 M, 20.0 mL) was added to a solution of 3.04 g 3,4,5,6-tetrahydropthalic anhydride in 40.0 mL THF at -78°, stirred for 1.5 h, treated with saturated aqueous NH4Cl solution, stirred at room temperature for 30 min to give, after workup, 3-(3-aminophenyl)-3-hydroxy-4,5,6,7-tetrahydro-2-benzofuran-1(3H)-

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 590408-04-1 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3-aminophenyl)methyl]-5,6,7,8-tetrahydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1
 CRN 590408-03-0
 CMF C15 H17 N3 O



CM 2
 CRN 75-75-2
 CMF C H4 O3 S




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

L3 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L3 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 365222-04-4 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L3 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:535075 CAPLUS
 DOCUMENT NUMBER: 139:285639
 TITLE: The imidazo[2,1-a]isoindole system. A new skeletal basis for antiparasitodal compounds
 AUTHOR(S): del Olmo, Esther; Armas, Marlon Garcia; Ybarra, Maria Ines; Lopez, Jose Luis; Oporto, Patricia; Gimenez, Alberto; Deharo, Eric; San Feliciano, Arturo
 CORPORATE SOURCE: Departamento de Química Farmacéutica, Facultad de Farmacia, Salamanca, 37007, Spain
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(16), 2769-2772
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:285639
 AB The in vitro antiparasitodal activity of some dihydrostilbenamides, phthalazinones, imidazo[2,1-a]isoindole and pyrimido[2,1-a]isoindole derivs. related to the natural dihydrostilbenoid isonothalaenic acid is reported. The evaluation was performed on cultures of F32 strain of Plasmodium falciparum and potent representative compds. were also evaluated in the ferriprotoporphyrin IX biomineralization inhibition test (FBIT). Compds. having the imidazo[2,1-a]isoindole skeleton were the most active and one compound of this group resulted to be as potent as chloroquine, but acting through a mechanism different that of the inhibition of heme biomineralization.
 IT 10001-31-7P 365222-04-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation and structure-activity relationship of imidazo[2,1-a]isoindole derivs. as antiparasitodal compds.)
 RN 10001-31-7 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:361428 CAPLUS
 DOCUMENT NUMBER: 137:279149
 TITLE: A facile synthesis of 4-diarylmethyl-1-(2H)phthalazinones from 2,2-diaryl-1,3-indanediones
 AUTHOR(S): Kundu, Sandip Kumar; Pramanik, Animesh; Patra, Amarendra
 CORPORATE SOURCE: Department of Chemistry, University of Calcutta, Kolkata, 700 009, India
 SOURCE: Synlett (2002), (5), 823-825
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:279149
 GI



AB Refluxing of 2,2-diaryl-1,3-indanediones in hydrazine hydrate for a brief period affords after ring cleavage/condensation reactions the 4-diarylmethyl-1-(2H)phthalazinones, e.g. I, in very high yield.
 IT 465498-69-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Synthesis of 4-diarylmethyl-1-(2H)phthalazinones from 2,2-diaryl-1,3-indanediones via ring cleavage/condensation reactions in presence of hydrazine hydrate)
 RN 465498-69-5 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(4-methoxyphenyl)(2,3,4-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:353439 CAPLUS
 DOCUMENT NUMBER: 136:355242
 TITLE: Preparation of phthalazinones as PARP inhibitors
 INVENTOR(S): Martin, Niall Morrison Barr; Smith, Graeme Cameron Murray; White, Charles Richard; Newton, Roger Frank; Douglas, Diane Gillian; Eversley, Penny Jane; Vile, Julia
 PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; Maybridge PLC
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036576	A1	20020510	WO 2001-GB4729	20011025
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CN, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2423279	AA	20020510	CA 2001-2423279	20011025
AU 2001095789	A5	20020515	AU 2001-95789	20011025
EP 1330442	A1	20030730	EP 2001-976521	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
GB 2384776	A1	20030806	GB 2003-9190	20011025
BR 2001015062	A	20040303	BR 2001-15062	20011025
NZ 525138	A	20040326	NZ 2001-525138	20011025
JP 2004513121	T2	20040430	JP 2002-539335	20011025
US 2002123325	A1	20021205	US 2001-21506	20011030
ZA 2003002112	A	20040220	ZA 2003-2112	20030317
NO 2003001498	A	20030402	NO 2003-1498	20030402
US 2006142293	A1	20060629	US 2006-352178	20060210
PRIORITY APPLN. INFO.:			GB 2000-26503	A 20001030
			US 2001-275066P	P 20010312
			US 2000-245662P	P 20001106
			WO 2001-GB4729	W 20011025
			US 2001-21506	A1 20011030

OTHER SOURCE(S): MARPAT 136:355242
 GI

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; A and B together represent (un)substituted fused aromatic ring; R1 = LR3 (wherein L = (CH2)nQm(CH2)p; n, m, p = 0-3, the sum of n, m and p = 1-3; Q = O, S, NH, CO; R3 = (un)substituted C5-20 aryl]; R2 = H, (un)substituted C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, etc-1, useful for inhibiting the activity of PARP (poly(ADP-ribose)synthase), were prepared General procedures for synthesis of I were described.


Biol. data such as IC50 values against PARP, and DEF which is a ratio of the enhancement of the cell growth inhibition elicited by test compds. in the presence of bleomycin compared to bleomycin alone, were given. E.g., the compound I [AB = benzo; R1 = 4-chlorobenzyl; R2 = H] showed IC50 of 1.8 μM against PARP, and DEF of 1.9.

IT 420846-57-7P 420846-60-2P 420846-61-3P
 420846-63-5P 420846-64-6P 420846-65-7P
 420846-67-9P 420846-69-1P 420846-70-4P
 420846-72-6P 420846-78-2P 420846-81-7P
 420846-82-8P 420846-83-9P 420846-84-0P
 420846-85-1P 420846-86-2P 420846-87-3P
 420846-89-5P 420846-90-8P 420846-91-9P
 420846-92-0P 420846-93-1P 420846-94-2P
 420846-95-3P 420846-96-4P 420846-97-5P
 420846-98-6P 420846-99-7P 420847-00-3P
 420847-01-4P 420847-02-5P 420847-03-6P
 420847-04-7P 420847-05-8P 420847-06-9P
 420847-07-0P 420847-08-1P 420847-09-2P
 420847-10-5P 420847-11-6P 420847-12-7P
 420847-13-8P 420847-14-9P 420847-15-0P
 420847-16-1P 420847-17-2P 420847-18-3P
 420847-19-4P 420847-20-7P 420847-21-8P
 420847-22-9P 420847-23-0P 420847-24-1P
 420847-25-2P 420847-26-3P 420847-27-4P
 420847-28-5P 420847-29-6P 420847-30-9P
 420847-31-0P 420847-32-1P 420847-33-2P
 420847-34-3P 420847-35-4P 420847-36-5P
 420847-37-6P 420847-38-7P 420847-39-8P
 420847-40-1P 420847-41-2P 420847-42-3P
 420847-43-4P 420847-44-5P 420847-45-6P
 420847-46-7P 420847-47-8P 420847-48-9P
 420847-49-0P 420847-50-3P 420847-51-4P
 420847-52-5P 420847-53-6P 420847-54-7P
 420847-55-8P 420847-56-9P 420847-57-0P
 420847-58-1P 420847-59-2P 420847-60-5P
 420847-61-6P 420847-62-7P 420847-63-8P
 420847-64-9P 420847-65-0P 420847-66-1P
 420847-67-2P 420847-68-3P 420847-69-4P
 420847-70-7P 420847-71-8P 420847-72-9P


L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

420847-73-0P 420847-74-1P 420847-75-2P
 420847-76-3P 420847-77-4P 420847-78-5P
 420847-79-6P 420847-80-9P 420847-82-1P
 420847-83-2P 420847-84-3P 420847-85-4P
 420847-86-5P 420847-87-6P 420847-88-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phthalazinones as PARP inhibitors)
 RN 420846-57-7 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[[3-(aminophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 420846-60-2 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 420846-61-3 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 420846-63-5 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 420846-64-6 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-(phenylmethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)

$$X' = OR^5$$

1, 2, 9


L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 420846-65-7 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-amino-4-(4-thiomorpholinyl)phenyl)methyl]- (9CI) (CA INDEX NAME)


$$X' = OCH_2R^5$$

422 1,




RN 420846-67-9 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-nitro-4-(1-pyrrolidinyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-69-1 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-methoxy-4-(phenylmethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 420846-70-4 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(4-fluoro-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-72-6 CAPLUS
CN Benzoic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 420846-78-2 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 420846-81-7 CAPLUS
 CN 2-Thiophenecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420846-82-8 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 420846-83-9 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-84-0 CAPLUS
 CN Acetamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420846-85-1 CAPLUS
 CN Benzeneacetamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-alpha-ethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-86-2 CAPLUS
 CN 1-(2H)-Phthalazinone, 4-[(3-(acetyloxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 420846-87-3 CAPLUS
 CN Benzoic acid, 4-fluoro-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-89-5 CAPLUS
 CN Decanoic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420846-90-8 CAPLUS
 CN Benzoic acid, 4-[(dipropylamino)sulfonyl]-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-91-9 CAPLUS
 CN Benzoic acid, 2-(4-methoxyphenoxy)-5-nitro-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420846-92-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-[(4-chlorophenyl)sulfonyl]-3-methyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-95-3 CAPLUS
 CN [3,5'-Bisoxazole]-4'-carboxylic acid, 3',5-dimethyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420846-96-4 CAPLUS
 CN 3-Furanicarboxylic acid, 5-(4-chlorophenyl)-2-(trifluoromethyl)-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-93-1 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-(2,3-dihydro-5-benzofuranyl)-4-methyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420846-94-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-(2-thienyl)-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-97-5 CAPLUS
 CN 6-Quinoxalinecarboxylic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420846-98-6 CAPLUS
 CN 2-Propenoic acid, 3-(2-chloro-3,4-dimethoxyphenyl)-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420846-99-7 CAPLUS
CN 4-Oxazolecarboxylic acid, 5-phenyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-00-3 CAPLUS
CN 1,4-Piperidinedicarboxylic acid, 4-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl] 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-01-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(4-methoxyphenyl)-5-methyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-02-5 CAPLUS
CN Benzoic acid, 4-hexyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 420847-03-6 CAPLUS
CN Benzoic acid, 4-propyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-04-7 CAPLUS
CN 4H-1,3-Benzodioxin-8-carboxylic acid, 6-fluoro-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 420847-05-8 CAPLUS
CN Benzoic acid, 2,4,5-trifluoro-3-methoxy-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-06-9 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-07-0 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-chloro-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-08-1 CAPLUS
CN cyclopropanecarboxylic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-09-2 CAPLUS
CN 3-Furancarboxylic acid, 5-methyl-2-(trifluoromethyl)-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-10-5 CAPLUS
CN Cyclobutanecarboxylic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-11-6 CAPLUS
CN Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-12-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-13-8 CAPLUS
CN 1,3-Benzodioxole-5-carboxylic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-14-9 CAPLUS
CN Octanoic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-15-0 CAPLUS
CN Butanoic acid, 4-chloro-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-16-1 CAPLUS
 CN 3-Isoxazolecarboxylic acid, 5-methyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-17-2 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[(1,1-dimethylethyl)-5-methyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-18-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 5-phenyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-19-4 CAPLUS
 CN Hexanoic acid, 2-ethyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-20-7 CAPLUS
 CN 1H-Indole-1,2-dicarboxylic acid, 2,3-dihydro-, 2-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl] 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 420847-21-8 CAPLUS
 CN Propanoic acid, 3-chloro-2,2-dimethyl-, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-22-9 CAPLUS
 CN 2-Butenic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl ester (9CI) (CA INDEX NAME)




RN 420847-23-0 CAPLUS
 CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-24-1 CAPLUS
 CN Urea, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 420847-25-2 CAPLUS
 CN Acetic acid, [2-[(5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-(4-morpholinyl)phenyl)amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-26-3 CAPLUS
 CN Cyclobutanecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420847-27-4 CAPLUS
 CN 3-Furancarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-5-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-28-5 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 4-bromo-N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-1-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 420847-29-6 CAPLUS
 CN 3-Isoxazolecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-30-9 CAPLUS
 CN 1,3-Benzodioxole-5-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420847-31-0 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-1-(1,1-dimethylethyl)-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-32-1 CAPLUS
 CN Hexanamide, N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 420847-33-2 CAPLUS
 CN Octanamide, N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-34-3 CAPLUS
 CN Propanamide, 2-chloro-N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]- (9CI) (CA INDEX NAME)




RN 420847-35-4 CAPLUS
 CN 2-Butenamide, N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-36-5 CAPLUS
 CN 2H-1,5-Benzodioxepin-7-carboxamide, N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 420847-37-6 CAPLUS
 CN 4-Pyridinecarboxamide, 2-chloro-N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-38-7 CAPLUS
 CN 4-Pyridinecarboxamide, 2-chloro-N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]- (9CI) (CA INDEX NAME)




RN 420847-39-8 CAPLUS
 CN Propanamide, 2-(4-chlorophenoxy)-N-[3-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-40-1 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 420847-41-2 CAPLUS
 CN Cyclohexanecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-42-3 CAPLUS
 CN 4H-1,3-Benzodioxin-8-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 420847-43-4 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-4-propyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-44-5 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2,4,5-trifluoro-3-methoxy- (9CI) (CA INDEX NAME)




RN 420847-45-6 CAPLUS
 CN 2-Propenamide, 3-(2-chloro-3,4-dimethoxyphenyl)-N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-46-7 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-4-hexyl- (9CI) (CA INDEX NAME)




RN 420847-47-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-48-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)




RN 420847-49-0 CAPLUS
CN 6-Quinolinecarboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-50-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]carbonyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)




RN 420847-51-4 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-1-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-52-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 420847-53-6 CAPLUS
CN 4-Oxazolecarboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-54-7 CAPLUS
CN [3,5'-Bisoxazole]-4'-carboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-3',5'-dimethyl- (9CI) (CA INDEX NAME)




RN 420847-55-8 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-(2-thienyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-56-9 CAPLUS
 CN 2-Thiazolecarboxamide,
 5-[(2,3-dihydro-5-benzofuranyl)-N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 420847-57-0 CAPLUS
 CN 3-Furancarboxamide, 5-(4-chlorophenyl)-N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-58-1 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 420847-59-2 CAPLUS
 CN 2-Thiophenecarboxamide,
 4-[(4-chlorophenyl)sulfonyl]-N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-60-5 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-3-(1,1-dimethylethyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 420847-61-6 CAPLUS
 CN 1H-Indole-3-carboxamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-62-7 CAPLUS
 CN Decanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420847-63-8 CAPLUS
 CN Benzamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-(4-methoxyphenoxy)-5-nitro- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-64-9 CAPLUS
 CN Butanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 420847-65-0 CAPLUS
 CN Propanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI)
 (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-66-1 CAPLUS
 CN Propanamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 420847-67-2 CAPLUS
 CN Urea,
 N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-68-3 CAPLUS
 CN Urea,
 N-[3-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420847-69-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]carbonylamino]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-70-7 CAPLUS
 CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)




RN 420847-71-8 CAPLUS
 CN Urea, N-(2,3-dihydro-5-benzofuranyl)-N'-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-72-9 CAPLUS
 CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 420847-73-0 CAPLUS
 CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-(2-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-74-1 CAPLUS
 CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 420847-75-2 CAPLUS
 CN Urea, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-N'-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-76-3 CAPLUS
 CN Urea, N-[4-(4-butyphenyl)]-N'-(3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl)- (9CI) (CA INDEX NAME)




RN 420847-77-4 CAPLUS
 CN Urea, N-butyl-N'-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-78-5 CAPLUS
 CN Methanesulfonamide, N-[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 420847-79-6 CAPLUS
 CN Acetamide, N-[4-[[[3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-80-9 CAPLUS
 CN 2-Thiophenesulfonamide, N-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]phenyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 420847-82-1 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-83-2 CAPLUS
 CN 1(2H)-Phthalazinone, 4-[(4-fluoro-3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 420847-84-3 CAPLUS
 CN Benzoic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-85-4 CAPLUS
 CN Benzamide, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 420847-86-5 CAPLUS
 CN Benzamide, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-(4-morpholinyl)-N-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 420847-87-6 CAPLUS
 CN Benzamide, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-(4-morpholinyl)-N-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 420847-88-7 CAPLUS
 CN Butanamide, 4-chloro-N-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:746588 CAPLUS
DOCUMENT NUMBER: 136:112202
TITLE: Anti-Trypanosoma activity of some natural stilbenoids and synthetic related heterocyclic compounds
AUTHOR(S): Olmo, E.; Armas, M. G.; Lopez-Perez, J. L.; Ruiz, G.; Vargas, F.; Gimenez, A.; Deharo, E.; Feliciano, A. S.
CORPORATE SOURCE: Departamento de Quimica Farmaceutica, Facultad de Farmacia, Salamanca, 37007, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(20), 2755-2757
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We report the anti-Chagasic activity of the natural dihydrostilbenoid isonothalaenic acid and several simple derivs., as well as that of some representative compds. of related synthetic series, with basic structures of benzaliphthalides, dihydrostilbamides, isoindoles, phthalazin-1-ones, imidazo[2,1-a]isoindoles and pyrimido[2,1-a]isoindoles. The evaluation was performed in vitro on cultures of epimastigote and trypomastigote forms of Trypanosoma cruzi. Some of the tested compds. resulted to be as potent as benznidazole (epimastigotes), and others were shown to be more active than gentian violet (trypomastigotes), used as reference drugs.


IT 10001-31-7 365222-04-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-Trypanosoma activity of natural stilbenoids and synthetic related heterocyclic compds.)

RN 10001-31-7 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 365222-04-4 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L3 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:612024 CAPLUS
DOCUMENT NUMBER: 135:285601
TITLE: Leishmanicidal activity of some stilbenoids and related heterocyclic compounds
AUTHOR(S): Munoz, V.; Deharo, E.; San Feliciano, A.
CORPORATE SOURCE: Departamento de Quimica Farmaceutica, Facultad de Farmacia, Salamanca, 37007, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(16), 2123-2126
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The authors have evaluated the leishmanicidal activity of some natural and semisynthetic dihydrostilbenoids and several compds. of other series of dihydrostilbamides, isoindoles, phthalazinones, imidazoisoindoles, and pyrimidoisoindoles. The evaluation was performed in vitro, on cultures of cutaneous, mucocutaneous and visceral strains of Leishmania spp. The most potent and selective compds. of these series were the dihydrostilbene piperidides.


IT 10001-31-7 365222-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(leishmanicidal activity of some stilbenoids and related heterocyclic compds.)

RN 10001-31-7 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 365222-04-4 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1966:499390 CAPLUS
DOCUMENT NUMBER: 65:99390
ORIGINAL REFERENCE NO.: 65:18600c-g
TITLE: Phthalazine derivatives
INVENTOR(S): Sigal, Max V., Jr.; Marchini, Paolo; Poet, Buford L.
PATENT ASSIGNEE(S): S. E. Massengill Co.
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3274185		19660920	US 1965-462162	19631008


GI For diagram(s), see printed CA issue.
AB The title compds. are prepared by treating the substituted phenylacetic acid

with the chosen substituted phthalic anhydride to give a substituted benzal phthalide which is then treated with NH_2NH_2 . A mixture of 31 g. phthalic anhydride, 48 g. 3,4-(MeO) $2\text{C}_6\text{H}_3\text{CH}_2\text{CO}_2\text{H}$ and 1 g. freshly fused AcONa was heated rapidly to 230° , then slowly to 240° , over a period of 2 hrs. The reaction was maintained at 240° until the distillation of H_2O ceased, then cooled to give 34 g. I (R = OMe), m. $132-3^\circ$ (absolute EtOH). This compound (35 g.) was dissolved in 200 ml. EtOH and 12 ml. NH_2NH_2 and the mixture refluxed 2 hrs. and cooled to give 34.5 g. II (R = OMe, R1 = OH, R2 = H), m. $193-4^\circ$ (absolute EtOH). A suspension of this compound (10 g.) in 40 ml. POCl_3 was refluxed 1 hr., excess POCl_3 evaporated in vacuo, the residue poured over crushed ice and neutralized with 10% Na_2CO_3 , and the mixture extracted with CHCl_3 to yield 9 g. II (R = OMe, R1 = Cl, R2 = H), m. $130-2^\circ$ (absolute EtOH). A solution of 6 g. II (R = R2 = OMe, R1 = Cl) in 50 ml. EtOH and 25 ml. NH_2NH_2 was refluxed 10 hrs. to yield 2 g. II (R = R2 = OMe, R1 = NHNH_2), m. $178-9^\circ$ (MeOH). Hydrogenation over 2 g. 5% Pd-C of a solution of 2 g. II (R = OMe, R1 = Cl) in 280 ml. EtOH containing 0.82 g. KOH, was followed by filtration, evaporation and addition of 2 ml. 30% NaOH. Extraction with C_6H_6 , concentration to 1.5 ml., and addition of 2 ml. Et $_2\text{O}$ yielded 0.9 g. II (R = R2 = OMe, R1 = H), m. $120-1^\circ$ (2:1 AcOEt-petr. ether). Similarly, the following compds. were also prepared (type, R, R1, R2, R3, and m.p. given): III -, -, OH, $333-5^\circ$ (decomposition); III -, -, Me, $249-54^\circ$ (decomposition); II, OEt, OH, H, -, $249-59^\circ$ (decomposition); II, OEt, Cl, H, -, 102° ; II, OMe, NHNH_2 , H, -, $150-2^\circ$; II, OEt, H, -, $125-7^\circ$. A solution of 2 g. II (R = R2 = OMe, R1 = NHNH_2) and 0.45 g. pyruvic acid in 150 ml. EtOH was refluxed 12 hrs. and evaporated to dryness to give 0.7 g. II (R = R2 = OMe, R1 = $\text{NHNH}_2\text{CMeCO}_2\text{H}$), m. $210-15^\circ$ (absolute MeOH). Similarly, the following compds. were obtained (type R, R1,

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R2, and m.p. given) II, OMe, 2-[(3-hydroxy-5-hydroxymethyl-2-methyl-4-pyridyl)methylene]hydrazino, H, $157-9^\circ$ (decomn.); II, OMe, 3,4,5-(MeO) $3\text{C}_6\text{H}_2\text{CH}_2\text{CH}_2\text{NNH}$, H, $159-60^\circ$. Those derivs. show a high degree of activity as antidepressants and can be used as tranquilizers with a sedative action and as blood pressure depressants.
IT 10001-31-7, 1-Phthalazinol, 4-venatryl- 10001-37-3, 1-Phthalazinol, 4-(3,4-diethoxybenzyl)- (preparation of)
RN 10001-31-7 CAPLUS
CN 1(2H)-Phthalazinone, 4-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 10001-37-3 CAPLUS
CN 1(4H)-Phthalazinone, 4-[(3,4-diethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1963:39759 CAPLUS
DOCUMENT NUMBER: 58:39759
ORIGINAL REFERENCE NO.: 58:6730e-g
TITLE: Synthesis of 2-methoxy- and 3-methoxydibenzo(a,d)-5-cycloheptatrienol
AUTHOR(S): Berti, Giancarlo; Da Settimo, Antonio; Gregori, Giuseppe; Mancini, Franco
CORPORATE SOURCE: Univ. Pisa, Italy
SOURCE: Annali di Chimica (Rome, Italy) (1962), 52, 514-34
CODEN: ANCRAT; ISSN: 0003-4592
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

GI For diagram(s), see printed CA issue.
AB The title compds. have tranquilizing and antihistaminic properties.
2-(m-Methoxybenzyl)phthalide is treated with NaOH to give 2-(m-MeOC $6\text{H}_4\text{CH}_2\text{CO}$)C $6\text{H}_4\text{CO}_2\text{H}$ which is reduced with NaBH_4 to 3-(m-methoxybenzyl)phthalide (I). I is dissolved in MeOH and treated with NaOH to yield trans Ia which is treated with H in presence of Adams Pt oxide to give 2-(m-MeOC $6\text{H}_4\text{CH}_2\text{CH}_2$)C $6\text{H}_4\text{CO}_2\text{H}$ (II). II is heated at 100° for 90 min. with polyphosphoric acid to yield 2-methoxy-dibenzo(a,d)-1,4-cycloheptadien-5-one, which is treated with N-bromosuccinimide and Bz_2O_2 and the mixture refluxed with Et $_3\text{N}$ to yield III, m. $77-7.5^\circ$. III (0.8 g.) is dissolved in 35 ml. MeOH, 0.12 g. KBH_4 in 4 ml. H_2O and 0.2 ml. 2N NaOH added, the mixture kept overnight, MeOH distilled, the residue taken up with H_2O , and crystallized to give 0.42 g. 5-ol analog of III (IV), m. $101-3^\circ$ (ligroine). Similarly prepared is 3-methoxy analog of IV, m. $120-2^\circ$ (C 6H_6 -petr. ether).
IT 94066-66-7, 1(2H)-Phthalazinone, 4-(m-methoxybenzyl) (preparation of)
RN 94066-66-7 CAPLUS
CN 1(2H)-Phthalazinone, 4-(m-methoxybenzyl)- (7CI) (CA INDEX NAME)

